Patent Grant
10208095
The present technology relates to methods of treating inflammatory disorders, including osteoarthritis. In particular, methods comprise use of solutions comprising cytokines, including such solutions derived from blood fractions obtained by non-centrifugal methods.
Inflammation is a complex cellular and biochemical process that occurs in the affected blood vessels and adjacent tissues in response to an injury or abnormal stimulation caused by a physical, chemical, or biologic agent, such as a pathogen, allergen or irritant. The inflammatory process includes local reactions and resulting morphologic changes in tissue; the destruction or removal of the causative agent; and the responses that lead to repair and healing. In most instances, inflammation is a beneficial and transient process, which subsides as the body attacks and overcomes an infectious or other harmful agent. However, in some instances, inflammation can be chronic self-perpetuating process, for example, as part of an ongoing degenerative process (such as arthritis) or autoimmune disease, leading to destruction of tissue. Chronic inflammation is associated with a variety of disorders, including rheumatoid arthritis, atherosclerosis, ischemic heart disease, periodontitis, colitis, and some cancers.
An inflammatory response consists of a cascade of biochemical events, involving the local vascular system and immune system, and various cells within the injured tissue. The process involves the release of numerous cell-derived mediators, including histamine, interferon-gamma, interleukin-8, leukotriene, nitric oxide, prostaglandins, tumor necrosis factor-alpha, and interleukin-1. In particular, interleukin-1 (IL-1) includes a family of cytokines that can stimulate lymphocytes and macrophages, activate phagocytes, increase prostaglandin production, contribute to degeneration of bone joints, increase bone marrow cell proliferation, and are involved in many chronic inflammatory conditions. IL-1 can be generated by macrophages, monocytes, and dendritic cells, and can be part of the inflammatory response against infection.
The mode of action of IL-1 can be mediated by interleukin-1 receptor antagonist protein (IL-1ra; also known as “IRAP”). IL-1ra binds to the same receptor on the cell surface as IL-1, and thus prevents IL-1 from sending a signal to that cell. IL-1ra is secreted from white blood cells, including monocytes, macrophages, neutrophils, polymorphonuclear cells (PMNs), and other cells, and can modulate a variety of IL-1 related immune and inflammatory responses, as described by Arend W P, Malyak M, Guthridge C J, Gabay C (1998) “Interleukin-1 receptor antagonist: role in biology” Annu. Rev. Immunol. 16: 27-55. Production of IL-1ra is stimulated by several substances including adherent immunoglobulin G (IgG), other cytokines, and bacterial or viral components. IL-1ra, as well as other cytokines such as soluble tumor necrosis factor receptor 1 (sTNF-R1), soluble tumor necrosis factor receptor 2 (sTNF-R2) and (soluble interleukin receptor II (sIL-1RII), is an important natural anti-inflammatory protein in arthritis, colitis, and granulomatous pulmonary disease.
IL-1ra can be used in the treatment of rheumatoid arthritis, an autoimmune disease in which IL-1 plays a key role, reducing inflammation and cartilage degradation associated with the disease. For example, Kineret™ (anakinra) is a recombinant, non-glycosylated form of IL-1ra (Amgen Manufacturing, Ltd., Thousand Oaks, Calif.). Various recombinant interleukin-1 inhibitors and methods of treatment are described in U.S. Pat. No. 6,599,873, Sommer et al., issued Jul. 29, 2003; U.S. Pat. No. 5,075,222, Hannum et al., issued Dec. 24, 1991; and U.S. Application Publication No. 2005/0197293, Mellis et al., published Sep. 8, 2005 In addition, methods for producing IL-1ra from body fluids, including the use of autologous fluids, are described in U.S. Pat. No. 6,623,472, Reinecke et al., issued Sep. 23, 2003; U.S. Pat. No. 6,713,246, Reinecke et al., issued Mar. 30, 2004; and U.S. Pat. No. 6,759,188, Reinecke et al., issued Jul. 6, 2004.
Many such treatments for inflammation are known in the art. Therapies known in the art may be directed to removal of the underlying irritant or agent causing the inflammatory reaction, or by mediating one or more aspects of the inflammatory response. Examples include glucocorticoid steroids (such as hydrocortisone, cortisone, prednisone, and beclomethasone), non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen), and immune selective anti-inflammatories. However, many such treatments present side effects, particularly during chronic administration, or have pharmacologic characteristics that limit their use. For example, while compositions and methods using IL-1ra are known in the art, they may be associated with issues regarding stability and half-life of IL-1ra as well as the amount and rate of IL-1ra provided. Moreover, many treatments do nothing to address the underlying causes of the inflammatory process. Accordingly, improved methods of treating inflammation are needed, offering one or more of improved efficacy, reduced side effects, and improved dosing characteristics.
The present technology provides methods for generating solutions rich in anti-inflammatory cytokines for use in treatment of inflammation and other disorders mediated by interleukin-1 and tumor necrosis factor-alpha. Methods for generating such solutions include contacting a liquid volume of cytokine-producing cells with a solid extraction material, removing the solid extraction material from the liquid, and freeze drying the liquid. The liquid volume of cytokine-producing cells is obtained from whole blood by non-centrifugal methods, such as filtration, antibody binding, and electrophoretic methods. Thus, the present technology provides methods for generating a solution rich in interleukin-1 receptor antagonist (IL-1ra) comprising:
In various embodiments, the anti-inflammatory cytokine composition comprises
Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings. It should be noted that the figures set forth herein are intended to exemplify the general characteristics of materials, compositions, devices, and methods among those of the present technology, for the purpose of the description of certain embodiments. These figures may not precisely reflect the characteristics of any given embodiment, and are not necessarily intended to fully define or limit specific embodiments within the scope of this technology.
The following description of technology is merely exemplary in nature of the composition, manufacture and use of one or more inventions, and is not intended to limit the scope, application, or uses of any specific invention claimed in this application or in such other applications as may be filed claiming priority to this application, or patents issuing therefrom. A non-limiting discussion of terms and phrases intended to aid understanding of the present technology is provided at the end of this Detailed Description.
The present technology relates to compositions, methods of making compositions, and methods of using compositions for the treatment of inflammatory disorders, and other disorders mediated by interleukin-1. In general, such compositions are made by a process comprising:
The present technology provides methods for treating inflammatory disorders other disorders mediated by interleukin-1 in humans or other mammalian subjects using compositions (herein referred to as “Protein Solutions”) comprising proteins dissolved, suspended or otherwise carried for delivery to a mammalian subject in a physiologically-acceptable medium. In various embodiments, such compositions comprise proteins (e.g., cytokines) that are native to whole blood in normal mammal subjects. Such compositions may also contain viable cells, including platelets, white blood cells, and combinations thereof.
In various embodiments, the Protein Solution comprises at least two proteins selected from the group consisting of IL-1ra, sTNF-RI, sTNF-RII (soluble tumor necrosis factor-receptor 2), IGF-I (insulin-like growth factor 1), EGF (epidermal growth factor), HGF (hepatocyte growth factor), PDGF-AB (platelet-derived growth factor AB), PDGF-BB (platelet-derived growth factor BB), VEGF (vascular endothelial growth factor), TGF-β1 (transforming growth factor-β1, and sIL-1RII (soluble interleukin receptor II), wherein the concentration of each protein in the composition is greater than the concentration of the protein in normal blood. While the concentration of every such protein in the composition may be greater than its respective concentrations in in normal blood, it is not necessary that the concentration of more than two of the proteins be greater than their respective concentrations in normal blood.
In various embodiments, the platelet-rich protein solution comprises the following components.
Protein concentrations can be measured using the methods known in the art. For example, Quantikine® human immunoassays (R&D Systems, Inc., Minneapolis, Minn.) may be used to assay for IL-1ra, IL-1β, IL-8, sTNF-RI, TNF-α, IL-6, sTNF-RII, IL-10, IL-13, and IL-4, according to the manufacturer's instructions. Immunoassays may be performed for hepatocyte growth factor and soluble IL-1RII.
The composition further preferably comprises viable white blood cells, lysed white blood cells, or both. In a preferred composition, the Protein Solution comprises monocytes, granulocytes, and platelets. In various embodiments, a Protein Solution comprises the following components.
It will be understood that this concentration is species specific. Further, it is understood that concentrations may vary among individual subjects. Thus, in methods comprising production of a Protein Solution from the blood or other tissue containing cytokine-producing cells, the concentration of proteins and cells in the Protein Solution may vary from those recited above; the values recited above are mean values for concentrations as may be seen in a population of subjects.
In various embodiments, the concentration of one or more of the proteins or other components in the Protein Solution is greater than the concentration of the component in normal blood. (Compositions with such higher concentrations of components are said to be “rich” in such components.) As referred to herein, the concentration of a component in “normal” blood or other tissue is the concentration found in the general population of mammalian subjects from which the tissue is obtained, e.g., in normal whole blood. In methods wherein the anti-inflammatory cytokine composition is derived from tissue from a specific subject, the “normal” concentration of a protein or cell may be the concentration in the blood of that individual before processing is performed to derive the protein or cell.
Thus, in various embodiments, the concentration of one or more components of the Protein Solution is greater than about 1.5 times, about 2 times, or about 3 times, greater than the concentration of the component in normal blood. For example, components may have greater concentrations in the compositions, relative to normal (whole) blood, as follows:
For example, a Protein Solution may comprise:
In some embodiments, the concentration of IL-1ra in the Protein Solution is preferably at least 5,000, or at least 10,000, times greater than the concentration of interleukin-1α in the Protein Solution. The ratio of IL-1ra:interleukin-1β (IL-1β) concentrations is preferably at least 100. In some embodiments, the concentration of IL-1ra in the Protein Solution is preferably at least 1500, or at least 8000, times greater than the concentration of IL-1β in the Protein Solution. The ratio of sIL-1RII:interleukin-1β (IL-1β) concentrations is preferably greater than 1. In some embodiments, the sIL-1RII in the Protein Solution is preferably at least 2000, or at least 45000, times greater the concentration of interleukin-1β in the Protein Solution.
The present technology provides Protein Solutions wherein one or more components of the Protein Solution are obtained from non-autologous sources, such as through recombinant or synthetic methods, or by isolation from allogeneic sources (i.e., from subjects of the same species as the subject to whom the solution is to be administered) or xenogeneic sources (i.e., from animal sources other than the species to whom the solution is to be administered). In some embodiments, the Protein Solutions consists, or consists essentially, of such allogeneic components. However, in various embodiments, the Protein Solution comprises one or more components (e.g., platelets) derived from the subject to whom the solution is to be administered in a treatment methods according to this technology. Such components are, accordingly, “autologous.” In some embodiments, the Protein Solution comprises mixtures of autologous and allogeneic components.
As discussed above, the Protein Solution is made by fractionating a liquid comprising cytokine-producing cells, to produce a protein solution comprising cytokines, such as IL1-ra. In various embodiments, Protein Solutions are made by derivation of one or more components from tissue comprising cytokine-producing cells. As referred to herein, a “cytokine producing tissue” is a tissue obtained from a mammalian subject, comprising cells that are capable of producing cytokines. Such cells include white blood cells, adipose stromal cells, bone marrow stromal cells, and combinations thereof. It is understood that white blood cells include monocytes, lymphocytes, and granulocytes such as neutrophils, eosinophils, and basophils. White blood cell useful in the methods of this technology preferably include monocytes and neutrophils. Cytokine producing tissues among those useful herein include blood, adipose tissue, bone marrow, and fractions thereof, as further discussed below.
Blood useful herein includes whole blood, plasma, platelet-rich plasma, platelet-poor plasma, and blood clots. In a preferred embodiment, methods of the present technology use platelet-rich plasma (PRP), containing white blood cells and platelets, comprising the buffy coat layer created by sedimentation of whole blood. Adipose tissue useful herein includes any fat tissue, including white and brown adipose tissue, which may be derived from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue sites. Bone marrow useful herein includes red marrow and yellow marrow. In a preferred embodiment, bone marrow is bone marrow concentrate, obtained from the red marrow of long bones, comprising hematopoietic and mesenchymal stems cells. As discussed above, compositions of the present technology may be made from blood, adipose, and bone marrow tissue from allogeneic sources, relative to the subject to be treated according to methods of this technology. Compositions may also be made from combinations of allogeneic and autologous tissues.
In some embodiments, methods comprise fractionating a liquid (a “cytokine cell suspension.”) comprising cells capable of producing cytokines, such as IL1-ra and sTNF-R1. As discussed above, such cells include white blood cells, adipose stromal cells, bone marrow stromal cells, and combinations thereof. In some embodiments, the cytokine cell suspension is a liquid comprising white blood cells. It should be understood that the cytokine cell suspension comprises cells and an extra-cellular liquid, regardless of the relative proportions of the cells and liquid. In some embodiments, the suspension may comprise primarily cells, with liquid being present as only a minor component, essentially wetting the cells. In some embodiments, the liquid may comprise two phases, consisting of a phase primarily consisting of liquid and a phase primarily consisting of cells, forming a suspension of cells in the liquid only upon agitation or other mixing.
Obtaining a Cytokine Cell Suspension
Obtaining cytokine-producing cells may be performed directly in some methods of this technology, whereby a health care practitioner or other individual performs isolation, processing, or other processes for creating the liquid, in a procedure that includes the contacting and isolating steps. In some embodiments, the processes for creating the liquid are performed contemporaneously with the contacting and isolating steps, as part of a point-of-care procedure, as discussed further herein. Alternatively, obtaining the liquid may be indirect, involving only the acquisition of the liquid for use in the contacting and isolating steps, wherein the processing to create the liquid has previously been performed by another party.
As discussed above, the methods of this technology comprise obtaining a liquid comprising cytokine-producing cells by non-centrifugal processing of a tissue containing cytokine-producing cells (e.g., white blood cells), obtained from a mammalian subject. As referred to herein, a “non-centrifugal method” comprises a process for obtaining tissue fractions comprising cytokine-producing cells from tissue without use of a centrifuge. In some embodiments, methods are “non-gravimetric,” wherein, based on physical, chemical or physicochemical properties of the cells other than density, wherein the concentration of white blood cells in the fraction are higher than the concentration of white blood cells in the tissue. Such non-gravimetric methods are, in particular, distinguished from methods wherein a white blood cell fraction is created by centrifugation of whole blood or other tissue. In some embodiments, the non-centrifugal method comprises a process solely based on such properties of white blood cells other than density.
In some embodiments, non-centrifugal methods useful herein include obtaining a volume of cytokine-producing cells and suspending the volume in a suitable medium for subsequent processing in the methods of this technology. In other embodiments, a fraction of cytokine-producing cells is isolated from tissue, wherein the fraction comprises cytokine-producing cells in the medium suitable for subsequent processing. The medium may be constituted so as to maintain viability of the cytokine-producing cells, including physiological saline and serum. Thus, in various embodiments, methods comprise:
A cytokine cell suspension may be prepared by admixing cells with a suitable liquid, using methods known in the art. For example, white blood cells may be isolated from whole blood by lysing red blood cells or by centrifugation of whole blood utilizing a density gradient aid. An example of a suitable density gradient aid is Ficoll-Paque™ PLUS medium (GE Healthcare Bio-Sciences, Piscataway, N.J., USA), which comprises a hydrophilic polysaccharide which aggregates red blood cells. For example, in such a method, whole blood may be diluted 1:1 with an appropriate buffer, such as phosphate buffered saline (PBS), in a container. A volume of Ficoll-Paque™ PLUS medium is added to a centrifuge tube. The whole blood:PBS mixture is then gently layered on top of the Ficoll-Paque™ PLUS medium. Care should be taken to ensure the Ficoll-Paque™ PLUS medium and whole blood:PBS layers do not mix. The centrifuge tube containing layers of Ficoll-Paque™ PLUS medium and whole blood:PBS is centrifuged to separate blood components. Centrifugation can be from about 25 to about 35 minutes at about 400×g. After centrifugation, the blood components are present in separate layers. The top most layer comprises plasma. Directly below the plasma is a buffy coat, which contains white blood cells. Directly below the buffy coat is the Ficoll-Paque™ PLUS medium, and below the Ficoll-Paque™ PLUS medium are the red blood cells. The buffy coat, containing white blood cells, such as mononuclear cells, is collected and placed in a sterile centrifuge tube. Optionally, the white blood cells can be washed one or more times by suspending the cells in PBS, pelleting the cells by centrifugation, and removing the supernatant. After the cells are washed, they can be re-suspended in an appropriate buffer, such as PBS, or in plasma.
In some cases, a density gradient may be used to further separate mononuclear and polymorphonuclear cells. White blood cells may also be prepared from whole blood using filtration; an example includes the Acelere™ MNC Harvest System filtration system (Pall Life Sciences, Ann Arbor, Mich., USA). White blood cells can also be obtained from bone marrow. The white blood cells may be then suspended in a suitable medium, such as plasma, so as to maintain their viability.
Methods for isolating a liquid comprising white blood cell from a tissue include filtration, antibody binding, and electrophoretic methods. Filtrations methods include size exclusion filters, such as hollow fiber arrays, including such filters known in the art. Commercially available filters include LeukoCatch® syringe filters (Watson Co., Ltd., Kobe, Japan), as described by Okuzaki, et al., BMC Clinical Pathology 2011, 11:9, incorporated herein by reference. The LeukoCatch® syringe filters comprise one or more Leukosorb® B Medium filters (Pall Corp, Port Washington, N.Y.) sandwiched between plastic stoppers and set at the bottom of a 10 ml syringe. Leukocytes, but not red blood cells are captured by the filter. Therefore, a LeukoCatch® syringe comprising a plunger can be used to aspirate a sample of whole blood, wherein the leukocytes are captured by the filter. Pushing the plunger down expels the red blood cells from the syringe, but not the leukocytes, which are retained in the filter. The leukocytes can be washed by aspirating phosphate buffered saline (PBS) by pulling the plunger up, and expelling the PBS by pushing the plunger down. Washing can be repeated one or more times. The leukocytes are then eluted by pulling elution buffer into the syringe, and then expelling the elution buffer, now containing leukocytes, into a clean and sterile container. Elution buffer can comprise 10 mM Tris-HCL (pH 7.5), 100 mM NaCl, 1% Triton X-100, 1 mM EDTA (pH 8.0), 0.1 mg/mL PMSF, 1 mM Aprotinin, 0.001 mg/ml leupeptin, 0.001 mg/ml pepstatin A, 1 mM NaF, 1 mM Na3VO4, and 10 mM β-glycerophosphate.
Another non-centrifugal method for generating a liquid volume comprising cytokine-producing cells comprises inducing electrical fields on electrically charged plates to separate cells based on their affinity for different electrical charges. In one such method as described by Wang, et al., Anal Chem. 2000 Feb. 15; 72(4): 832-839 dielectrophoretic field-flow-fractionation (DEP-FFF) can be used to fractionate leukocytes from blood. Leukocytes have different dielectric properties than erythrocytes. Microelectrodes produce DEP forces that levitate blood cells in a thin chamber comprising a top plate and a bottom plate separated by a spacer. When the cells reach an equilibrium height based on their dielectric properties, a carrier fluid moves through the chamber. Cells at different heights travel through the chamber at different velocities, resulting in their separation. For example, whole blood can be diluted 1:1000 in a sucrose buffer. When placed in the thin chamber, a DEP field of about 10 kHz can be applied for DEP-FFF. With a flow rate of about 0.5 ml/min, leukocytes can be enriched 35-fold.
Yet another non-centrifugal method for generating a liquid volume comprising cytokine-producing cells comprises the use of magnetic particles, such as magnetic beads, that specifically bind to cytokine-producing cells. The magnetic particle can be coupled to a molecule that specifically binds to mononuclear leukocytes. The molecule and be a ligand or an antibody. For example, U.S. Pat. No. 7,867,765, by Faustman, et al., issued Jan. 11, 2011 describes magnetic beads conjugated to proteins that bind specifically to white blood cell surface proteins. Antibody or ligand conjugated beads are added to a container containing a sample comprising cytokine-producing cells. The antibody or ligand binds to cytokine-producing cells. After incubating for a preselected period of time, a magnet is placed or held on the outside of the container. While the magnet is placed or held on the outside of the container, the container is tilted to decant contents that are not attracted to the magnet. The content that is attracted to the magnet, white blood cell conjugated magnetic beads, can be washed one or more times with an appropriate buffer, such as PBS. Optionally, the magnetic beads can be separated from the cytokine-producing cells. Finally, the mononuclear cytokine-producing cells can be resuspended in an appropriate buffer, for example PBS or plasma.
In some embodiments, obtaining cytokine cell suspension comprises filtering blood to isolate white blood cells, and suspending the white blood cells in plasma to form a white blood cell suspension. A device for creating such whole blood cell suspension is shown in
According to various embodiments, therefore, the syringe 200 can have a volume of whole blood positioned therein. The filter 220 can filter and collect white blood cells from whole blood volume, as the whole blood volume is forced (e.g. expressed) through the filter 220. The filter 220 can be positioned at or on the end of the syringe 200. Once the syringe 200 that included the volume of whole blood has expressed the whole blood through the filter 220, the syringe 200 and the filter 220 can be interconnected with a fluid source for backwashing the filter 220. The plunger 202 can then be moved in a second or direction to fill the syringe 200 to pass the backwashing fluid, such as saline or plasma, through the filter 220 to fill the syringe with the backwashed material from the filter, including the white blood cells.
In addition to expressing the whole blood through the syringe and filter into a separate container, and backwashing with a backwashing material from a different source, various components or fractions of the whole blood sample can also be used to backwash the filter. For example, if whole blood is passed through the filter in a first direction, the remaining plasma and/or buffy coat in the whole blood can be used to backwash the filter. Collection of fractionation of the remaining whole blood portions into plasma and/or buffy coat and/or red blood cells can be performed for the various devices such as those disclosed in U.S. Pat. No. 7,845,499; and U.S. Patent Application Publication No. 2011/0192804, published Aug. 11, 2011. For example, with reference to
Once the separation tube 230 is filled with the whole blood after it has passed through the white blood filter 220, the tube 230 can be centrifuged to separate the filtered whole blood into selected fractions, such as a red blood cells fraction 300, a buffy coat 310, and a plasma fraction 320. The buoy system 240 can be used to separate the three fractions 300, 310, and 320 for withdrawal from the fractionation tube 230. The fractionated filtered blood, as illustrated in
It is understood that the filter 220 can be positioned between the syringe 200 and the respective ports 260, 270 such that the material withdrawn from the separation tube 230 will backwash the filter 220.
As discussed above, the fractions within the separation tube 230 can be based upon separation of the filtered whole blood sample positioned within the tube 230. According to various embodiments, the factions can include at least a red blood cell fraction 300, a buffy coat fraction as the fraction 310 and the plasma fraction as the fraction 320. Accordingly, according to various embodiments, the buffy coat fraction 310 can be used to backwash the filter 220, as illustrated in
Contacting with a Solid Extraction Material
In some embodiments, fractionating a cytokine cell suspension comprises contacting the liquid with a solid extraction material. Such processes comprise:
The solid extraction material can include various materials that provide a particular surface area to contact the cells. The solid extraction material may be a continuous material or may be discontinuous and comprise a plurality of separate particles. For example, the solid extraction material may be in the form of a plurality of beads, fibers, powder, a porous material, or a surface of a container comprising the liquid containing the cells. The solid extraction material may comprise geometric forms having various cross-sectional shapes, such as spherical, oval, or polygonal, among others. The solid extraction material can also comprise a continuous porous network, similar to a sponge, or can include a plurality of individual porous particles. The solid extraction material may also provide a larger surface area by being porous in comparison to a non-porous material.
In some embodiments, the solid extraction material includes particles having a large aspect ratio, for example, where the particles are needle-like in shape. The solid extraction material may also be formed as long fibers and may be or take a form similar to glass wool.
In some cases, the solid extraction material can comprise the internal walls of a container holding the cytokine cell suspension. For example, the solid extraction material may comprise the lumen of a syringe that contains the cytokine cell suspension. Other containers include tubes, such as centrifuge tubes, or a blood fractionation device or concentrator assembly as described elsewhere herein.
Where the solid extraction material is a continuous material, such as a porous sponge-like material, the solid extraction material can be used in an amount sufficient to absorb or adsorb or include substantially the entire liquid volume of cytokine-producing cells within the pores or interstices of the solid extraction material. Where the solid extraction material is a discontinuous material, such as a plurality of particles, the solid extraction material can be combined with the liquid containing the cells to form a slurry-like composition. The slurry can vary in consistency from paste-like, having a high-solids fraction, to a readily flowable slurry having a low-solids fraction.
The solid extraction material can provide a large surface area with which to contact the cells. However, in some cases, the solid extraction material can be further treated to increase its surface area, for example, by physically or chemically etching or eroding the surface of the solid extraction material. With respect to chemical etching, a corrosive agent can be used to modify the surface of the solid extraction material depending on the nature of the material. The modified surface may be produced by employing an alkali or an acid, for example chromosulphonic acid, in particular about 20% to about 80% in strength, preferably about 50% chromosulphonic acid. The solid extraction material can be incubated with the corrosive agent for about 5 min to about 30 min in order to chemically etch the surface and increase the surface area. The solid extraction material can then be washed to remove the corrosive agent. For example, the solid extraction material can include the internal walls of a container for holding the cytokine cell suspension where the internal walls are etched to subsequently increase the surface area in contact with the liquid.
Various polymers, metals, ceramics, and glasses can be used as the solid extraction material. In some embodiments, the solid extraction material comprises a hygroscopic material. Examples of suitable solid extraction material materials include glasses, minerals, polymers, metals, and polysaccharides. Minerals include corundum and quartz. Polymers include polystyrene, polyethylene, polyvinyl chloride, polypropylene, and polyacrylamide. Metals include titanium. Polysaccharides include dextran and agarose. A preferred solid extraction material comprises, or consists essentially of, polyacrylamide, as further described below.
The solid extraction material may comprise, for example, continuous solid extraction material of glass or a plurality of glass particles, glass wool, a continuous solid extraction material of metal such as titanium, a plurality of metal beads, metal powder, and combinations thereof. A continuous solid extraction material of metal can include a block or other three-dimensional shape formed of porous metal or metal alloys with an open cell structure. The solid extraction material may include various beads or particles of various sizes including substantially spherical beads. Beads include polystyrene beads, polyacrylamide beads, glass beads, metal (e.g., titanium) beads, or any other appropriate beads. Beads may be any size appropriate for the container and the amount of cytokine cell suspension being used. In some instances, bead sizes can range from about 0.001 millimeters to about 3 millimeters in diameter. Where the bead size is sufficiently small, the beads can appear more like a powder.
Polyacrylamide beads used as the solid extraction material can be formed by polymerizing acrylamide monomer using controlled and standardized protocols as known in the art to produce relatively uniform beads formed of polyacrylamide gel. In general, polyacrylamide is formed by polymerizing acrylamide with a suitable bifunctional crosslinking agent, most commonly N,N′-methylenebisacrylamide (bisacrylamide). Gel polymerization is usually initiated with ammonium persulfate and the reaction rate is accelerated by the addition of a catalyst, such as N,N,N′,N′-tetramethylethylenediamine (TEMED). In various embodiments, polyacrylamide beads comprise 0.5 micromole of carboxyl groups per milliliter of beads, imparting a slight anionic character (negative charge). The beads are also typically resistant to changes in pH, and are stable in many aqueous and organic solutions. By adjusting the total acrylamide concentration, the polyacrylamide gel can be formed in a wide range of pore sizes. Moreover, the polyacrylamide beads can be formed in many sizes and can have relatively uniform size distributions. Bead size may range from several micrometers in diameter to several millimeters in diameter. For example, various types of Bio-Gel™ P polyacrylamide gel beads (Bio-Rad Laboratories, Hercules, Calif., USA) have particle sizes ranging from less than about 45 μm up to about 180 μm. Polyacrylamide beads are also available from SNF Floerger (Riceboro, Ga., USA), Pierce Biotechnology, Inc. (Rockford, Ill., USA), and Polymers, Inc. (Fayetteville, Ark., USA).
Once polymerized, polyacrylamide beads can be dried and stored in a powder-like form. The dry beads are insoluble in water but can swell considerably upon being rehydrated. Rehydration returns the polyacrylamide beads to a gel consistency that can be from about two to about three times the dry state size. Thus, dry polyacrylamide beads (i.e., desiccating polyacrylamide beads) may be used to absorb a portion of a liquid volume, including solutes smaller than the bead pore size, and can serve to concentrate IL-1ra and other proteins produced by the cytokine-producing cells. For example, combining dry polyacrylamide beads with the blood and/or platelet-rich plasma in step 230 activates production of IL-1ra by the cytokine-producing cells and also reduces the total liquid volume as the dry beads rehydrate and swell.
Without limiting the scope, mechanism or function of the present technology, it has been discovered that surface contact with the solid extraction material can activate the cells and the solid extraction material can, in some cases, assist in the separation and concentration of the resulting Protein Solution rich in cytokines, including IL-1ra. For example, in the case of a porous solid extraction material, a portion of the liquid comprising the cells can enter the pores and remain therein. Cells in the liquid may contact this additional surface area. In some embodiments, the pores are too small for the cells to enter, but a portion of the liquid can enter the pores. Liquid can be removed from the solid extraction material and pores by centrifuging, for example.
The solid extraction material is preferably sterilized, using techniques among known in the art, in order to prevent contamination of the cytokine cell suspension. For example, heat and pressure sterilization methods, such as autoclaving, may be used depending on the particular composition of the solid extraction material. Alternative methods, such as chemical sterilization or irradiation, can be used where the solid extraction material may be adversely affected by the autoclaving process.
In some embodiments, the cytokine cell suspension is incubated with solid extraction material for a time effective to remove a portion of the liquid. The incubation may be carried out over a period from about 30 seconds to about 72 hours and may be carried out at a temperature from about 20° C. to about 41° C. For example, the incubation may be from about one minute to about 48 hours, from about 2 minutes to about 24 hours, from about 5 minutes to about 12 hours, from about 10 minutes to about 6 hours, from about 15 minutes to about 5 hours, from about 30 minutes to about 4 hours, from about 1 hour to about 3 hours, or from about 2 hours to about 2.5 hours. In some embodiments, the incubation is conducted at about 37° C. In some embodiments the liquid is not incubated, but is contacted with the solid extraction material for only so long as necessary to perform subsequent processing. The contacting may occur at ambient conditions, e.g., at a temperature of about 20-25° C.
In some embodiments, the cytokine cell suspension and the solid extraction material are agitated to more thoroughly mix these components during contact. The agitation may be accomplished by inverting, shaking, rocking, stirring, or vortexing the liquid and solid extraction material. Agitation may increase contact of the cells within the liquid with the solid extraction material. Agitation may be performed once, repeated multiple times, repeated periodically, or may be continuous. The liquid comprising the cells and the solid extraction material may also be agitated while the liquid is stimulated with an electromagnetic field, as described below. Additional aspects and features relating to producing protein-rich solutions using polyacrylamide beads and other solid extraction materials are described in: U.S. Patent Application Publication No. 2009/0220482, Higgins et al., published Sep. 3, 2009; U.S. Patent Application Publication No. 2010/0055087, Higgins et al., published Mar. 4, 2010; U.S. Patent Application Publication 2011/0052561, Hoeppner, published Mar. 3, 2011; International Application Publication 2012/030593, Higgins et al., published Mar. 8, 2012; and U.S. Patent Application Publication 2012/0172836, Higgins et al., published Jul. 5, 2012.
Contacting of the liquid containing cytokine-producing cells with the solid extraction material may be performed using a suitable container or other apparatus to effect the contact. Contacting may be performed in a continuous process wherein a flow of the liquid is passed over or through the solid extraction material, or the liquid and solid extraction material may be contained in a vessel. As discussed above, the vessel may comprise the solid extraction material, or may merely serve as a container holding the beads or other forms of the material. Containers useful in the present technology include those known in the art, such as the Plasmax™ Plus Plasma Concentrator, commercially available from Biomet Biologics, LLC (Warsaw, Ind., USA) and may include those devices and methods of use as described in U.S. Pat. No. 7,553,413, Dorian et al., issued Jun. 30, 2009; and U.S. Pat. No. 7,694,828, Swift et al., issued Apr. 13, 2010.
Such a device is shown in
During use, a fluid 455 containing cytokine-producing cells and, optionally, platelets is injected to the upper chamber 405 via the inlet port 430 and mixed with the polyacrylamide beads 450. The fluid 455 and polyacrylamide beads 450 may be mixed by rotating the agitator stem 420 and the gel bead agitator 425, to help mix the fluid 455 and beads 450. The mixed fluid 455 and polyacrylamide beads 450 are then incubated for the desired time at the desired temperature. The device 400 is then centrifuged so that liquid passes to the lower chamber 410 while the polyacrylamide beads 450 are retained by a filter 445, thereby separating the polyacrylamide beads 150 from the resulting solution 460 of IL-1ra and other proteins that collects in the lower chamber 410. The solution 460 may be removed from the device via outlet port 435.
The cytokine cell suspension can be stimulated with an electromagnetic field, before or during the contacting of the liquid with a solid extraction material. Thus, in some embodiments, stimulation of the liquid comprising the cells can be performed prior to contacting the liquid and the solid extraction material. However, it is preferred that at least a portion of the contacting step and at least a portion of the stimulating step overlap in time such that the liquid comprising the cells is concurrently in contact with the solid extraction material and stimulated with the electromagnetic field.
Stimulating the cytokine cell suspension with an electromagnetic field may involve various forms of electromagnetic stimulation, such as a pulsed electromagnetic field or a capacitively coupled electromagnetic field. In some embodiments, the liquid is stimulated using a power source coupled to a stimulation coil. The current passing through the coil produces a pulsing magnetic field which induces in the liquid a pulsing electric field. The coil may partially surround the liquid as it is held within a container, such as a tube or syringe. The coil may be integrated into to the container holding the cytokine cell suspension or may be removable. For example, a plastic tube can be formed with an integrated coil or the coil can be temporarily coupled to the container or placed within the container; for example, the tube can be configured so that the coil can be snapped onto the container. The power source can be coupled to the coil as needed to perform the stimulating step.
Stimulation of the liquid with an electromagnetic field may also include placing at least two electrodes across the liquid. Electrical energy may then be applied to the electrodes so as to capacitively couple the electrodes and generate the electromagnetic field there between. The electromagnetic field is therefore able to pass through the liquid so as to increase the rate and/or amount of cytokine production. In other embodiments, electrodes can be used to produce a direct current or one or more coils can be used to produce a pulsed electromagnetic field.
The strength of the electromagnetic field during stimulation can be at least about 0.5 microvolts per centimeter, whether produced by direct current, capacitively coupled current, or pulsed electromagnetic field. In the case of a direct current electrode, the amplitude of the current can be from about 1 to about 200 microamperes, and in some embodiments, the amplitude may be from about 20 to about 100 microamperes. In still further embodiments, the current may be about 20, about 60, or about 100 microamperes. It should be understood, however, that the amplitude of the current may be of other suitable magnitudes.
The electromagnetic field applied during the stimulating step may be constant or vary over time. For example, a sinusoidal time varying electromagnetic field can be applied using the electrodes placed across the liquid. Such a sinusoidal time varying electromagnetic field can have a peak voltage across the electrodes from about 1 volt to about 10 volts, and in some embodiments, the peak voltage can be about 5 volts. The corresponding electric field produced can have an amplitude of from about 0.1 millivolt per centimeter (mV/cm) to about 100 mV/cm, and in some embodiments can be about 20 mV/cm. The sinusoidal time varying electric field may have a frequency of from about 1,000 Hz to about 200,000 Hz, and in some embodiments the frequency may be about 60,000 Hz.
The electromagnetic field applied to the liquid may also be a pulsed electromagnetic field. The pulsed electromagnetic field can be induced using an external coil and a pulse generator. In this regard, a pulsed electromagnetic field may have a pulse duration of from about 10 microseconds per pulse to about 2000 microseconds per pulse. The pulse duration in one embodiment can be about 225 microseconds. The pulses may include electromagnetic bursts, in which a burst can comprise from 1 pulse to about 200 pulses. Alternatively, the electromagnetic field may have bursts that comprise from about 10 pulses to about 30 pulses. In this regard, in one embodiment each burst may comprise about 20 pulses.
The frequency at which bursts in the pulsed electromagnetic are applied may vary. In this regard, bursts can be repeated at a frequency of from about 1 Hz to about 100 Hz in some embodiments, and can be repeated at a frequency of about 10 Hz to about 20 Hz in other embodiments. Furthermore, bursts can repeat at a frequency of about 1.5 Hz, about 15 Hz or about 76 Hz. A burst can have a duration from about 10 microseconds up to about 40,000 microseconds. In this regard, a burst can have a duration of about 4.5 milliseconds.
Suitable devices for generating a capacitively coupled electromagnetic field include SpinalPak® spinal stimulator (EBI, L.P., Parsippany, N.J.) or a DC stimulation device such as an SpF4 XL IIb spinal fusion stimulator (EBI, L.P., Parsippany, N.J.). Pulsed electromagnetic fields can be produced using various known methods and apparatuses, such as using a single coil or a pair of Helmholtz coils. For example, a suitable apparatus includes the EBI Bone Healing System Model 2001 healing device (EBI, L.P., Parsippany, N.J.) and the Biomet Trauma and Biomet Spine (BTBS) (Biomet, Warsaw, Ind.) stimulation coil. With respect to direct current, an electric field may be generated using any known device for generating a direct current electric field, such as for example, the Osteogen™ implantable bone growth stimulator (EBI, L.P., Parsippany, N.J.). Other suitable devices for generating electromagnetic fields may be used.
Electromagnetic stimulation of the cytokine cell suspension can be continued and/or repeated as desired with respect to contacting the liquid and the solid extraction material. It should be understood, however, that the step of stimulating the liquid with an electromagnetic field includes fields other than, or in addition to, electric or electromagnetic fields associated with ambient conditions (such the electromagnetic fields generated by casual exposure to radios, telephones, desktop computers or similar devices).
In some embodiments, both the contacting and stimulating steps as shown in
The present technology also provides compositions comprising a Protein Solution and a second component comprising active materials, physiological carriers, and combinations thereof. In some embodiments, compositions comprise a safe and effective amount of the Protein Solution and a safe and effective amount of a second active. A “safe and effective” amount of a component is an amount that is sufficient to have the desired therapeutic effect in the human or other mammalian subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this technology. The specific safe and effective amount of the component will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the nature of concurrent therapy (if any), the specific components used, the specific route of administration and dosage form, the carrier (if any) employed, and the desired dosage regimen.
Active materials among those useful herein include biologics and pharmaceutical actives. Biologics include blood fractions, such as PRP, blood products, and concentrated bone marrow aspirate (cBMA).
Accordingly, in some embodiments, the present technology provides compositions comprising a safe and effective amount of a Protein Solution and a safe and effective amount of cBMA. An autologous therapeutic composition comprises APS and cBMA in an APS:cBMA ratio of about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9 or about 1:10. Alternatively, the APS:cBMA ratio can be about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1 or about 10:1. cBMA can include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, cytokine-producing cells, fibroblasts, reticulocytes, adipose cells, or endothelial cells.
In some embodiments, the cBMA and Protein Solution may be produced simultaneously. Thus, in reference to
Pharmaceutical actives among those useful herein include herein include organic molecules, proteins, peptides, peptidomimetics, nucleic acids, nucleoproteins, antisense molecules, polysaccharides, glycoproteins, lipoproteins, carbohydrates and polysaccharides, botanical extracts, and synthetic and biologically engineered analogs thereof, living cells (other than cytokine-producing cells stromal cells) such as chondrocytes, bone marrow cells, viruses and virus particles, natural extracts, and combinations thereof. Specific non-limiting examples of bioactive materials include hormones, antibiotics and other anti-infective agents, hematopoietics, thrombopoietics, antiviral agents, antitumor agents (chemotherapeutic agents), antipyretics, analgesics, anti-inflammatory agents, antiallergy agents, vasodilators, cytokines, growth factors, gene regulators, vitamins, minerals and other nutritionals, nutraceuticals and combinations thereof. In particular, actives include bronchodilators (such as albuterol, levabuterol, irbuterol, ipatropium, salmeterol, and formoterol), glucocorticosteroids (such as mometasone, fluticasone, budesonide, and beclomethosone), antibiotics, antivirals, and combinations thereof. In some embodiments, compositions may comprise growth factors in addition to those present in the Protein Solution, such Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-β), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), and Bone Morphogenetic Proteins (BMPs).
In some embodiments, Protein Solutions comprise one or more cytokines from synthetic or recombinant sources. In particular, by way of example, a Protein Solution may comprise interleukin-1 receptor antagonist (IL-1ra) that is synthetic or recombinant, or isolated from autologous, allogeneic or xenogeneic blood or other biologic sources, aside from the methods described above. For example, Kineret™ (anakinra) is a recombinant, non-glycosylated form of IL-1ra, sold by Amgen Manufacturing, Ltd. (Thousand Oaks, Calif.). Various recombinant interleukin-1 inhibitors and methods of treatment are described in U.S. Pat. No. 6,599,873, Sommer et al., issued Jul. 29, 2003; U.S. Pat. No. 5,075,222, Hannum et al., issued Dec. 24, 1991; and U.S. Application Publication No. 2005/0197293, Mellis et al., published Sep. 8, 2005. In addition, methods for producing IL-1ra from body fluids, including the use of autologous fluids, are described in U.S. Pat. No. 6,623,472, Reinecke et al., issued Sep. 23, 2003; U.S. Pat. No. 6,713,246, Reinecke et al., issued Mar. 30, 2004; and U.S. Pat. No. 6,759,188, Reinecke et al., issued Jul. 6, 2004. When an allogeneic anti-inflammatory cytokine composition is to be generated, multiple sources of IL-1ra from multiple subjects may be pooled together.
In some embodiments, Protein Solutions comprise one or more cytokines derived from a tissue comprising cytokine-producing cells, by contacting a cytokine cell suspension with a solid extraction material, wherein the liquid is isolated from a tissue using centrifugation or other gravimetric methods. Liquids comprising cytokine-producing cells include blood, adipose tissue, bone marrow, and fractions thereof, such as platelet-rich plasma. Solid extraction materials include those described above. Devices for making blood fractions by centrifugation of whole blood are described in U.S. Pat. No. 7,992,725, Leach et al., issued Aug. 9, 2011, U.S. Pat. No. 7,374,678, Leach, issued May 20, 2008; U.S. Pat. No. 7,179,391 to Leach et al., issued Feb. 20, 2007; U.S. Pat. No. 7,992,725, Leach et al., issued Aug. 9, 2011; U.S. Pat. No. 7,806,276, Leach et al., issued Oct. 5, 2010; and U.S. Pat. No. 8,048,297, Leach et al., issued Nov. 1, 2011. Methods for making solutions rich in cytokines are described in U.S. Patent Application Publication No. 2009/0220482, Higgins et al., published Sep. 3, 2009; U.S. Patent Application Publication No. 2010/0055087, Higgins et al., published Mar. 4, 2010; U.S. Patent Application Publication 2011/0052561, Hoeppner, published Mar. 3, 2011; International Application Publication 2012/030593, Higgins et al., published Mar. 8, 2012; and U.S. Patent Application Publication 2012/0172836, Higgins et al., published Jul. 5, 2012.
Other methods for producing components of Protein Solutions useful herein are described in the following co-filed applications, the disclosures of which are incorporated by reference herein: Compositions and methods useful in aspects of the present technology are also described in the following applications filed concurrently with this disclosure: U.S. patent application Ser. No. 13/840,562, Binder et al., Methods and Non-Immunugenic Compositions for Treating Inflammatory Diseases; U.S. patent application Ser. No. 13/841,083, Landrigan, et al., Treatment of Inflammatory Respiratory Disease Using Protein Solutions; U.S. patent application Ser. No. 13/837,005, Woodell-May et al., Methods and Acellular Compositions for Treating Inflammatory Disorders; U.S. patent application Ser. No. 13/837,480, Treatment of Pain Using Protein Solutions; U.S. patent application Ser. No. 13/840,129, Matusuka, et al., Treatment of Collagen Defects Using Protein Solutions; and U.S. patent application Ser. No. 13/841,103, Landrigan, et al., Treatment of Peripheral Vascular Disease Using Protein Solutions, all of which are incorporated by reference herein.
The compositions may comprise a carrier material, in addition to any liquid comprising the Protein Solution. It should be understood that in various embodiments of the present technology, methods of treatment employ the Protein Solution as comprised and made above, without further carrier, by direct injection or other application to the site of treatment. However, in other embodiments, an additional carrier material may be used for such reasons as for ease of administration, to facilitate administration using a particular delivery device, enhancing activity, an increasing the length of time the Protein Solution remains at the site of administration. Carriers among those useful herein include saline, hyaluronic acid, collagen, buffers (such as Hank's Buffer), cell culture media, blood products (such as PRP and platelet poor plasma), and mixtures thereof.
Protein Solutions, and compositions comprising Protein Solutions may be sterilized prior to administration, by any suitable method. For example, a Protein Solution may be sterilized by including a sterile filter to process the product made by the processes described above. In some embodiments, an antibiotic may be included in the solid extraction material during the contacting step described above, or may be added at one or more of the various steps in the methods and treatments described herein. Alternatively, or in addition, the Protein Solution may be produced asceptically.
Protein Solutions and compositions comprising Protein Solutions may also be lyophilized (freeze drying, or cryodesiccation) after production, using methods among those known in the art. Thus, the Protein Solution can be lyophilized after it is isolated from the solid extraction material. When freeze dried, the anti-inflammatory cytokine composition can be hydrated with a suitable media 170, at a time before administration or at a time of administration. Hydration may be accomplished by mixing the composition with a solution including saline, buffers, blood, blood fractions, bone marrow aspirate, concentrated bone marrow aspirate, and combinations thereof.
In some embodiments, a crypreservative storage solution is be added to the Protein Solution, to provide stability for subsequent storage at reduced temperatures. Suitable storage solutions include those in the art, such as glycerol and dimethylsulfoxide (DMSO). The composition may be stored at reduced temperatures, such as from about 1° C. to about 6° C. In some embodiments, the composition is stored under liquid nitrogen, at about −80° C. Preferably, the cryopreservative storage solution is removed from the Protein Solution prior to administration to a mammalian subject. Removal of the storage solution may be performed by methods including those known in the art for processing stored blood comprising cryopreservatives. Washing may be performed using a wash solution, such as saline. In such embodiments, the blood type of the subject to be treated may be matched to the blood type of the donor from whom the cytokine cell suspension was obtained.
The present technology provides methods for the treatment of an inflammatory disorder or other disorder mediated by IL1-ra in a human or other mammalian subject, comprising administration of a Protein Solution of the present technology to the subject. Methods include treating an inflammatory disorder using a Protein Solution that is made by contacting a cytokine cell suspension with a solid extraction material, wherein the liquid is whole blood, bone marrow aspirate, adipose tissue, or fractions thereof.
Such diseases may be characterized by elevated neutrophil counts. Without limiting the mechanism, utility or function of the present technology, the methods and treatments of this technology mediate the effects of interleukin-1 and its role in the inflammation cascade. As generally discussed above, interleukin-1 (IL-1) includes a family of cytokines that can stimulate lymphocytes, neutrophils, and macrophages, activate phagocytes, increase airway fibrosis, promote lymphocyte nodules in the airways, increase production of both MMP-9 and MMP-12, and are involved in many chronic inflammatory conditions. IL-1 can be generated by macrophages, monocytes, and dendritic cells, and can be part of the inflammatory response against infection. See, Lappalainen et al., “Interleukin-1β Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 4, pages 311-318 (April 2005).
The mode of action of IL-1 can be mediated by IL-1ra. IL-1ra binds to the same receptor on the cell surface as IL-1, and thus prevents IL-1 from sending a signal to that cell. IL-1ra is secreted from cytokine-producing cells, including monocytes, macrophages, neutrophils, polymorphonuclear cells (PMNs), and other cells, and can modulate a variety of IL-1 related immune and inflammatory responses, as described by Arend W P, Malyak M, Guthridge C J, Gabay C (1998) “Interleukin-1 receptor antagonist: role in biology” Annu. Rev. Immunol. 16: 27-55. Production of IL-1ra is stimulated by several substances including adherent immunoglobulin G (IgG), other cytokines, and bacterial or viral components. Likewise, the mode of action of TNF-α can be mediated by sTNF-RI and sTNF-RII, which prevent TNF-α from binding to membrane bound TNF-RI and/or TNF-RII.
Examples of inflammatory disorders treated by the methods of this technology include rheumatoid arthritis, osteoarthritis, osteolytis, tendonitis, synovitis, peripheral vascular disease, and inflammatory respiratory diseases (such as chronic obstructive pulmonary disease, fibrosis, emphysema, acute respiratory distress syndrome, and pneumonia). Treatment methods also include the prevention, reduction or elimination of pain associated with various disorders, such as pain associated with traumatic injury, muscle strain, arthritis (rheumatoid arthritis and osteoarthritis), synovitis, sacroiliac joint disorders, back disorders, post-surgical injections, tendon injections, sports medicine procedure (for example, ACL repair, MCL repair, BTB repair, patella repair, or cartilage repair), contusions, muscle strains, post traumatic osteoarthritis. Methods also include stimulation of chondrocyte production at the site of a collagen defect, such as defects at joints associated with arthritis, injuries or surgical procedures.
In some embodiments, methods of the present technology comprise administration of a Protein Solution to the site of a tissue defect to prevent or treat a disorder associated with IL-1ra. As referred to herein, such “tissue defects” include any condition involving tissue which is inadequate for physiological or cosmetic purposes. Examples of such defects include those that are congenital, those that result from or are symptomatic of disease, disorder, or trauma, and those that are consequent to surgical or other medical procedures. Embodiments include treatment for vascular, bone, skin, nerve, and organ tissue defects. Examples of such defects include those resulting from osteoporosis, spinal fixation procedures, hip and other joint replacement procedures, chronic wounds, fractures, sclerosis of tissues and muscles, and spinal cord or other nerve injury. In various embodiments, the compositions and methods of this invention may be used in methods associated with the repair bone or cartilage defects.
In various embodiments, methods are for the treatment of inflammatory disorders in a human. In other embodiments, treatment is for non-human mammals, such as companion, working, and sports animals. For example, such methods of this technology may be used for the treatment of inflammatory disorders in horses.
The present technology also provides point-of-care methods for making a Protein Solution. As referred to herein, a “point-of-care method” wherein the processes of the present technology are performed at a time proximate to the administration of the Protein Solution to the subject being treated. Such methods may be performed at a location proximate, such as in the same room (for example, bed side) or otherwise immediately adjacent, to the mammalian subject to be transfused with the RBCs. In various embodiments, a “proximate time” may be, for example, within 12 hours, within 8 hours, within 2 hours, within 1 hour or within 30 minutes of administration of the Protein Solution to the subject.
In some embodiments, the Protein Solution is administered with a concomitant therapy. Such therapies include, for example, the administration of pharmaceutical actives or biologics, as described above. In some embodiments, concomitant therapies are administered concurrently with a Protein Solution. For example, methods may comprise administration of a Protein Solution with a safe and effective amount of an active selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatories, antibiotics, antivirals, and combinations thereof.
In some embodiments, methods comprise administration of a Protein Solution with concentrated bone marrow aspirate, as described above. For example, cBMA and a Protein Solution may be administered concomitantly. Accordingly, in some embodiments, the present technology provides compositions comprising a safe and effective amount of a Protein Solution and a safe and effective amount of cBMA. An autologous therapeutic composition comprises APS and cBMA in an APS:cBMA ratio of about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9 or about 1:10. Alternatively, the APS:cBMA ratio can be about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1 or about 10:1. cBMA can include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulocytes, adipose cells, or endothelial cells. Methods for producing cBMA among those useful herein are described in U.S. Application Publication No. 2006/0278588, Woodell-May, published Dec. 14, 2006.
Methods of the present technology generally comprise administration of a Protein Solution to the site of inflammation in a mammalian subject. Administration of the Protein Solution can be performed with any suitable device, including such devices known in the art for topical delivery of compositions to the muscle, joint, vascular, lung or other tissue. For example, topical delivery for treatment of inflammation or pain associated with joint disorders may comprise injection of a Protein Solution at or near the joint. Treatment for inflammatory respiratory diseases may comprise delivery of a Protein Solution by endotracheal tubes, inhalers and nebulizers.
The headings (such as “Introduction” and “Summary”) and sub-headings used herein are intended only for general organization of topics within the present disclosure, and are not intended to limit the disclosure of the technology or any aspect thereof. In particular, subject matter disclosed in the “Introduction” may include novel technology and may not constitute a recitation of prior art. Subject matter disclosed in the “Summary” is not an exhaustive or complete disclosure of the entire scope of the technology or any embodiments thereof. Classification or discussion of a material within a section of this specification as having a particular utility is made for convenience, and no inference should be drawn that the material must necessarily or solely function in accordance with its classification herein when it is used in any given composition.
The disclosure of all references, including published and pending patents and patent applications, cited in this disclosure are incorporated by reference herein.
The description and specific examples, while indicating embodiments of the technology, are intended for purposes of illustration only and are not intended to limit the scope of the technology. Equivalent changes, modifications and variations of specific embodiments, materials, compositions and methods may be made within the scope of the present technology, with substantially similar results. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features, or other embodiments incorporating different combinations of the stated features. Specific examples are provided for illustrative purposes of how to make and use the compositions and methods of this technology and, unless explicitly stated otherwise, are not intended to be a representation that given embodiments of this technology have, or have not, been made or tested.
As used herein, the words “prefer” or “preferable” refer to embodiments of the technology that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology.
As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
Although the open-ended term “comprising,” as a synonym of non-restrictive terms such as including, containing, or having, is used herein to describe and claim embodiments of the present technology, embodiments may alternatively be described using more limiting terms such as “consisting of” or “consisting essentially of.” Thus, for any given embodiment reciting materials, components or process steps, the present technology also specifically includes embodiments consisting of, or consisting essentially of, such materials, components or processes excluding additional materials, components or processes (for consisting of) and excluding additional materials, components or processes affecting the significant properties of the embodiment (for consisting essentially of), even though such additional materials, components or processes are not explicitly recited in this application. For example, recitation of a composition or process reciting elements A, B and C specifically envisions embodiments consisting of, and consisting essentially of, A, B and C, excluding an element D that may be recited in the art, even though element D is not explicitly described as being excluded herein. Further, as used herein the term “consisting essentially of” recited materials or components envisions embodiments “consisting of” the recited materials or components.
A” and “an” as used herein indicate “at least one” of the item is present; a plurality of such items may be present, when possible. “About” when applied to values indicates that the calculation or the measurement allows some slight imprecision in the value (with some approach to exactness in the value; approximately or reasonably close to the value; nearly). If, for some reason, the imprecision provided by “about” is not otherwise understood in the art with this ordinary meaning, then “about” as used herein indicates at least variations that may arise from ordinary methods of measuring or using such parameters.
As referred to herein, ranges are, unless specified otherwise, inclusive of endpoints and include disclosure of all distinct values and further divided ranges within the entire range. Thus, for example, a range of “from A to B” or “from about A to about B” is inclusive of A and of B. Disclosure of values and ranges of values for specific parameters (such as temperatures, molecular weights, weight percentages, etc.) are not exclusive of other values and ranges of values useful herein. It is envisioned that two or more specific exemplified values for a given parameter may define endpoints for a range of values that may be claimed for the parameter. For example, if Parameter X is exemplified herein to have value A and also exemplified to have value Z, it is envisioned that Parameter X may have a range of values from about A to about Z. Similarly, it is envisioned that disclosure of two or more ranges of values for a parameter (whether such ranges are nested, overlapping or distinct) subsume all possible combination of ranges for the value that might be claimed using endpoints of the disclosed ranges. For example, if Parameter X is exemplified herein to have values in the range of 1-10, or 2-9, or 3-8, it is also envisioned that Parameter X may have other ranges of values including 1-9, 1-8, 1-3, 1-2, 2-10, 2-8, 2-3, 3-10, and 3-9.
| Number | Name | Date | Kind |
|---|---|---|---|
| 593333 | Park | Nov 1897 | A |
| 1468313 | Fritz | Sep 1923 | A |
| 1593814 | Robert | Jul 1926 | A |
| 2722257 | Lockhart | Nov 1955 | A |
| 3013557 | Pallotta | Dec 1961 | A |
| 3141846 | Laven, Jr. | Jul 1964 | A |
| 3159159 | Cohen | Dec 1964 | A |
| 3300051 | Mitchell | Jan 1967 | A |
| 3409165 | Creith | Nov 1968 | A |
| 3420374 | Umeda | Jan 1969 | A |
| 3441143 | Kudiaty | Apr 1969 | A |
| 3469369 | Flodin et al. | Jul 1969 | A |
| 3508653 | Coleman | Apr 1970 | A |
| 3545671 | Ross | Dec 1970 | A |
| 3583627 | Wilson | Jun 1971 | A |
| 3596652 | Winkelman | Aug 1971 | A |
| 3647070 | Adler | Mar 1972 | A |
| 3654925 | Holderith | Apr 1972 | A |
| 3661265 | Greenspan | May 1972 | A |
| 3706305 | Berger et al. | Dec 1972 | A |
| 3706306 | Berger et al. | Dec 1972 | A |
| 3723244 | Breillatt | Mar 1973 | A |
| 3741400 | Dick | Jun 1973 | A |
| 3779383 | Ayres | Dec 1973 | A |
| 3785549 | Latham | Jan 1974 | A |
| 3814248 | Lawhead | Jun 1974 | A |
| 3849072 | Ayres | Nov 1974 | A |
| 3850369 | Bull et al. | Nov 1974 | A |
| 3879295 | Glover et al. | Apr 1975 | A |
| 3887466 | Ayres | Jun 1975 | A |
| 3894952 | Ayres | Jul 1975 | A |
| 3896733 | Rosenberg | Jul 1975 | A |
| 3897337 | Ayres | Jul 1975 | A |
| 3897343 | Ayres | Jul 1975 | A |
| 3909419 | Ayres | Sep 1975 | A |
| 3929646 | Adler | Dec 1975 | A |
| 3931010 | Ayres et al. | Jan 1976 | A |
| 3931018 | North, Jr. | Jan 1976 | A |
| 3935113 | Ayres | Jan 1976 | A |
| 3937211 | Merten | Feb 1976 | A |
| 3941699 | Ayres | Mar 1976 | A |
| 3945928 | Ayres | Mar 1976 | A |
| 3951801 | Ayres | Apr 1976 | A |
| 3957654 | Ayres | May 1976 | A |
| 3962085 | Liston et al. | Jun 1976 | A |
| 3965889 | Sachs | Jun 1976 | A |
| 3972812 | Gresl, Jr. | Aug 1976 | A |
| 3982691 | Schlutz | Sep 1976 | A |
| 4001122 | Griffin | Jan 1977 | A |
| 4020831 | Adler | May 1977 | A |
| 4046699 | Zine, Jr. | Sep 1977 | A |
| 4055501 | Cornell | Oct 1977 | A |
| 4059108 | Latham, Jr. | Nov 1977 | A |
| 4066549 | Oeser et al. | Jan 1978 | A |
| 4077396 | Wardlaw et al. | Mar 1978 | A |
| 4088582 | Murty | May 1978 | A |
| 4146172 | Cullis et al. | Mar 1979 | A |
| 4152270 | Cornell | May 1979 | A |
| 4154690 | Ballies | May 1979 | A |
| 4159896 | Levine et al. | Jul 1979 | A |
| 4187979 | Cullis et al. | Feb 1980 | A |
| 4189385 | Greenspan | Feb 1980 | A |
| 4203840 | Stoeppler et al. | May 1980 | A |
| 4204537 | Latham, Jr. | May 1980 | A |
| 4225580 | Rothman et al. | Sep 1980 | A |
| 4229298 | Bange | Oct 1980 | A |
| 4269718 | Persidsky | May 1981 | A |
| 4294707 | Ikeda et al. | Oct 1981 | A |
| 4298598 | Schwarz et al. | Nov 1981 | A |
| 4300717 | Latham, Jr. | Nov 1981 | A |
| 4303193 | Latham, Jr. | Dec 1981 | A |
| 4314823 | Rich, Jr. | Feb 1982 | A |
| 4322298 | Persidsky | Mar 1982 | A |
| 4332351 | Kellogg | Jun 1982 | A |
| 4362567 | Schwarz et al. | Dec 1982 | A |
| 4364832 | Ballies | Dec 1982 | A |
| 4377572 | Schwarz et al. | Mar 1983 | A |
| 4379849 | Heimreid | Apr 1983 | A |
| 4411794 | Schwinn et al. | Oct 1983 | A |
| 4414976 | Schwarz et al. | Nov 1983 | A |
| 4416654 | Schoendorfer | Nov 1983 | A |
| 4417981 | Nugent | Nov 1983 | A |
| 4424132 | Iriguchi | Jan 1984 | A |
| 4427650 | Stroetmann | Jan 1984 | A |
| 4427651 | Stroetmann | Jan 1984 | A |
| 4442655 | Stroetmann | Apr 1984 | A |
| 4443345 | Wells | Apr 1984 | A |
| 4445550 | Davis et al. | May 1984 | A |
| 4446021 | Aufderhaar et al. | May 1984 | A |
| 4453927 | Sinko | Jun 1984 | A |
| 4453939 | Zimmerman et al. | Jun 1984 | A |
| 4464167 | Schoendorfer | Aug 1984 | A |
| 4511662 | Baran et al. | Apr 1985 | A |
| 4537767 | Rothman et al. | Aug 1985 | A |
| RE32089 | Blatt et al. | Mar 1986 | E |
| 4577514 | Bradley et al. | Mar 1986 | A |
| 4610656 | Mortensen | Sep 1986 | A |
| 4617009 | Ohlin | Oct 1986 | A |
| 4627879 | Rose et al. | Dec 1986 | A |
| 4631055 | Redl et al. | Dec 1986 | A |
| 4632761 | Bowers | Dec 1986 | A |
| 4639316 | Eldegheidy | Jan 1987 | A |
| 4650678 | Fuhge et al. | Mar 1987 | A |
| 4655211 | Sakamoto et al. | Apr 1987 | A |
| 4672969 | Dew | Jun 1987 | A |
| 4675117 | Neumann et al. | Jun 1987 | A |
| 4680025 | Kruger | Jul 1987 | A |
| 4708799 | Gerlach et al. | Nov 1987 | A |
| 4714457 | Alterbaum | Dec 1987 | A |
| 4722790 | Cawley et al. | Feb 1988 | A |
| 4724317 | Brown | Feb 1988 | A |
| 4735616 | Eibl et al. | Apr 1988 | A |
| 4735726 | Duggins | Apr 1988 | A |
| 4738655 | Brimhall et al. | Apr 1988 | A |
| 4755300 | Fischel et al. | Jul 1988 | A |
| 4755301 | Bowers | Jul 1988 | A |
| 4770779 | Ichikawa et al. | Sep 1988 | A |
| 4776964 | Schoendorfer et al. | Oct 1988 | A |
| 4818291 | Iwatsuki et al. | Apr 1989 | A |
| 4818386 | Burns | Apr 1989 | A |
| 4828710 | Itoh et al. | May 1989 | A |
| 4832851 | Bowers | May 1989 | A |
| 4834890 | Brown et al. | May 1989 | A |
| 4839058 | Cawley et al. | Jun 1989 | A |
| 4844818 | Smith | Jul 1989 | A |
| 4846780 | Galloway et al. | Jul 1989 | A |
| 4846835 | Grande | Jul 1989 | A |
| 4850952 | Figdor et al. | Jul 1989 | A |
| 4853137 | Ersson | Aug 1989 | A |
| 4871462 | Fischel et al. | Oct 1989 | A |
| 4874368 | Miller et al. | Oct 1989 | A |
| 4877520 | Burns | Oct 1989 | A |
| 4879031 | Panzani | Nov 1989 | A |
| 4900453 | Sedlmayer | Feb 1990 | A |
| 4902281 | Avoy | Feb 1990 | A |
| 4909251 | Seelich | Mar 1990 | A |
| 4915847 | Dillon et al. | Apr 1990 | A |
| 4917801 | Luderer et al. | Apr 1990 | A |
| 4928603 | Rose et al. | May 1990 | A |
| 4929242 | Desecki et al. | May 1990 | A |
| 4933291 | Daiss et al. | Jun 1990 | A |
| 4939081 | Figdor et al. | Jul 1990 | A |
| 4943273 | Pages | Jul 1990 | A |
| 4946601 | Fiehler | Aug 1990 | A |
| 4950220 | Wells et al. | Aug 1990 | A |
| 4957637 | Cornell | Sep 1990 | A |
| 4957638 | Smith | Sep 1990 | A |
| 4973168 | Chan | Nov 1990 | A |
| 4983157 | Pober et al. | Jan 1991 | A |
| 4983158 | Headley | Jan 1991 | A |
| 4985153 | Kuroda et al. | Jan 1991 | A |
| 5000970 | Shanbhag et al. | Mar 1991 | A |
| 5002571 | O'donnell, Jr. | Mar 1991 | A |
| 5019243 | Mcewen et al. | May 1991 | A |
| 5024613 | Vasconcellos et al. | Jun 1991 | A |
| 5030215 | Morse et al. | Jul 1991 | A |
| 5030341 | Mcewen et al. | Jul 1991 | A |
| 5039401 | Columbus et al. | Aug 1991 | A |
| 5045048 | Kaleskas | Sep 1991 | A |
| 5047004 | Wells | Sep 1991 | A |
| 5053127 | Schoendorfer et al. | Oct 1991 | A |
| 5053134 | Luderer et al. | Oct 1991 | A |
| 5071570 | Shiraki et al. | Dec 1991 | A |
| 5075222 | Hannum et al. | Dec 1991 | A |
| 5080262 | Herold et al. | Jan 1992 | A |
| 5086784 | Levine et al. | Feb 1992 | A |
| 5100564 | Pall et al. | Mar 1992 | A |
| 5104375 | Wolf et al. | Apr 1992 | A |
| 5112484 | Zuk, Jr. | May 1992 | A |
| 5112490 | Turpen | May 1992 | A |
| 5131907 | Williams et al. | Jul 1992 | A |
| 5137832 | Levine et al. | Aug 1992 | A |
| 5141645 | Shiraki et al. | Aug 1992 | A |
| 5147290 | Jonsson | Sep 1992 | A |
| 5152905 | Pall et al. | Oct 1992 | A |
| 5156613 | Sawyer | Oct 1992 | A |
| 5165938 | Knighton | Nov 1992 | A |
| 5171456 | Hwang et al. | Dec 1992 | A |
| 5173295 | Wehling | Dec 1992 | A |
| 5178602 | Wells | Jan 1993 | A |
| 5185001 | Galanakis | Feb 1993 | A |
| 5188583 | Guigan | Feb 1993 | A |
| 5190057 | Sarfarazi | Mar 1993 | A |
| 5190759 | Lindblad et al. | Mar 1993 | A |
| 5197985 | Caplan | Mar 1993 | A |
| 5203825 | Haynes | Apr 1993 | A |
| 5204537 | Bennet et al. | Apr 1993 | A |
| 5206023 | Hunziker | Apr 1993 | A |
| 5207638 | Choksi et al. | May 1993 | A |
| 5217426 | Bacehowski et al. | Jun 1993 | A |
| 5217627 | Pall et al. | Jun 1993 | A |
| 5219328 | Morse et al. | Jun 1993 | A |
| 5226877 | Epstein | Jul 1993 | A |
| 5226914 | Caplan et al. | Jul 1993 | A |
| 5234608 | Duff | Aug 1993 | A |
| 5236604 | Fiehler | Aug 1993 | A |
| 5251786 | Sarrine | Oct 1993 | A |
| 5258126 | Pall et al. | Nov 1993 | A |
| 5260420 | Burnouf-radosevich et al. | Nov 1993 | A |
| 5269927 | Fiehler | Dec 1993 | A |
| 5271852 | Luoma, II | Dec 1993 | A |
| 5279825 | Wehling | Jan 1994 | A |
| 5281342 | Biesel et al. | Jan 1994 | A |
| 5290552 | Sierra et al. | Mar 1994 | A |
| 5290918 | Bui-khac | Mar 1994 | A |
| 5298171 | Biesel | Mar 1994 | A |
| 5304372 | Michalski et al. | Apr 1994 | A |
| 5316674 | Pall et al. | May 1994 | A |
| 5318524 | Morse et al. | Jun 1994 | A |
| 5318782 | Weis-fogh | Jun 1994 | A |
| 5321126 | Van Dommelen et al. | Jun 1994 | A |
| 5322620 | Brown et al. | Jun 1994 | A |
| 5330974 | Pines et al. | Jul 1994 | A |
| 5344752 | Murphy | Sep 1994 | A |
| 5354483 | Furse | Oct 1994 | A |
| 5359032 | Dayer et al. | Oct 1994 | A |
| 5370221 | Magnusson et al. | Dec 1994 | A |
| 5370802 | Brown | Dec 1994 | A |
| 5372945 | Alchas et al. | Dec 1994 | A |
| 5376263 | Fischel | Dec 1994 | A |
| 5387187 | Fell et al. | Feb 1995 | A |
| 5393674 | Levine et al. | Feb 1995 | A |
| 5395923 | Bui-khac et al. | Mar 1995 | A |
| 5403272 | Deniega et al. | Apr 1995 | A |
| 5405607 | Epstein | Apr 1995 | A |
| 5409833 | Hu et al. | Apr 1995 | A |
| 5411885 | Marx | May 1995 | A |
| 5417650 | Gordon | May 1995 | A |
| 5420250 | Lontz | May 1995 | A |
| 5443481 | Lee | Aug 1995 | A |
| 5454958 | Fiehler | Oct 1995 | A |
| 5456693 | Conston et al. | Oct 1995 | A |
| 5456885 | Coleman et al. | Oct 1995 | A |
| 5474687 | Van Vlasselaer | Dec 1995 | A |
| 5480378 | Weis-fogh et al. | Jan 1996 | A |
| 5484383 | Fitch, Jr. et al. | Jan 1996 | A |
| 5486359 | Caplan et al. | Jan 1996 | A |
| 5494578 | Brown | Feb 1996 | A |
| 5494592 | Latham, Jr. et al. | Feb 1996 | A |
| 5501371 | Schwartz-feldman | Mar 1996 | A |
| 5505685 | Antwiler | Apr 1996 | A |
| 5510102 | Cochrum | Apr 1996 | A |
| 5520885 | Coelho et al. | May 1996 | A |
| 5525477 | Hassouna | Jun 1996 | A |
| 5533518 | Vogler | Jul 1996 | A |
| 5560830 | Coleman et al. | Oct 1996 | A |
| 5571418 | Lee et al. | Nov 1996 | A |
| 5575778 | Hardt et al. | Nov 1996 | A |
| 5577513 | Van Vlasselaer | Nov 1996 | A |
| 5585007 | Antanavich et al. | Dec 1996 | A |
| 5588958 | Cunningham et al. | Dec 1996 | A |
| 5589462 | Patat et al. | Dec 1996 | A |
| 5599558 | Gordinier et al. | Feb 1997 | A |
| 5601711 | Sklar et al. | Feb 1997 | A |
| 5601727 | Bormann et al. | Feb 1997 | A |
| 5603845 | Holm | Feb 1997 | A |
| 5607579 | Latham, Jr. et al. | Mar 1997 | A |
| 5614106 | Payrat et al. | Mar 1997 | A |
| 5618663 | Delmas | Apr 1997 | A |
| 5632895 | Tsukagoshi et al. | May 1997 | A |
| 5632905 | Haynes | May 1997 | A |
| 5641414 | Brown | Jun 1997 | A |
| 5641622 | Lake et al. | Jun 1997 | A |
| 5643192 | Hirsh | Jul 1997 | A |
| 5643193 | Papillon et al. | Jul 1997 | A |
| 5645540 | Henniges et al. | Jul 1997 | A |
| 5646004 | Van Vlasselaer | Jul 1997 | A |
| 5648223 | Van Vlasselaer | Jul 1997 | A |
| 5649903 | Deniega et al. | Jul 1997 | A |
| 5663051 | Vlasselaer | Sep 1997 | A |
| 5674173 | Hlavinka et al. | Oct 1997 | A |
| 5707331 | Wells et al. | Jan 1998 | A |
| 5707647 | Dunn et al. | Jan 1998 | A |
| 5707876 | Levine | Jan 1998 | A |
| 5716616 | Prockop et al. | Feb 1998 | A |
| 5723331 | Tubo et al. | Mar 1998 | A |
| 5724988 | Dennehey et al. | Mar 1998 | A |
| 5733466 | Benebo et al. | Mar 1998 | A |
| 5733545 | Hood, III | Mar 1998 | A |
| 5736033 | Coleman et al. | Apr 1998 | A |
| 5738784 | Holm et al. | Apr 1998 | A |
| 5738796 | Bormann et al. | Apr 1998 | A |
| 5750025 | Holmes et al. | May 1998 | A |
| 5750658 | Coelho et al. | May 1998 | A |
| 5762798 | Wenthold et al. | Jun 1998 | A |
| 5785700 | Olson | Jul 1998 | A |
| 5786217 | Tubo et al. | Jul 1998 | A |
| 5788662 | Antanavich et al. | Aug 1998 | A |
| 5792344 | Holm | Aug 1998 | A |
| 5792450 | Wilson et al. | Aug 1998 | A |
| 5795489 | Holm | Aug 1998 | A |
| 5795571 | Cederholm-Williams et al. | Aug 1998 | A |
| 5795751 | Apel | Aug 1998 | A |
| 5811094 | Caplan et al. | Sep 1998 | A |
| 5811151 | Hendriks et al. | Sep 1998 | A |
| 5817519 | Zelmanovic et al. | Oct 1998 | A |
| 5823986 | Peterson | Oct 1998 | A |
| 5824084 | Muschler | Oct 1998 | A |
| 5830359 | Knight et al. | Nov 1998 | A |
| 5833866 | Brown | Nov 1998 | A |
| 5834418 | Brazeau et al. | Nov 1998 | A |
| 5837150 | Langley et al. | Nov 1998 | A |
| 5840502 | Van Vlasselaer | Nov 1998 | A |
| 5842477 | Naughton et al. | Dec 1998 | A |
| 5846427 | Kessler et al. | Dec 1998 | A |
| 5853600 | Mcneal et al. | Dec 1998 | A |
| 5860937 | Cohen | Jan 1999 | A |
| 5863892 | Stern et al. | Jan 1999 | A |
| 5865785 | Bischof | Feb 1999 | A |
| 5885239 | Headley et al. | Mar 1999 | A |
| 5889584 | Wardlaw | Mar 1999 | A |
| 5895346 | Wells et al. | Apr 1999 | A |
| 5899874 | Jonsson | May 1999 | A |
| 5900245 | Sawhney et al. | May 1999 | A |
| 5906934 | Grande et al. | May 1999 | A |
| 5916557 | Berlowitz-tarrant et al. | Jun 1999 | A |
| 5916743 | Lake et al. | Jun 1999 | A |
| 5918622 | Perez | Jul 1999 | A |
| 5924972 | Turvaville et al. | Jul 1999 | A |
| 5934803 | Hutter | Aug 1999 | A |
| 5938621 | Kelly et al. | Aug 1999 | A |
| 5951160 | Ronk | Sep 1999 | A |
| 5955032 | Kelly et al. | Sep 1999 | A |
| 5955436 | Kunkle, Jr. | Sep 1999 | A |
| 5958250 | Brown et al. | Sep 1999 | A |
| 5958253 | Holm | Sep 1999 | A |
| 5961210 | Mccardel et al. | Oct 1999 | A |
| 5980734 | Itoh | Nov 1999 | A |
| 5980757 | Brown et al. | Nov 1999 | A |
| 5985315 | Patat et al. | Nov 1999 | A |
| 5997544 | Nies et al. | Dec 1999 | A |
| 6007811 | Sawyer et al. | Dec 1999 | A |
| 6010627 | Hood, III | Jan 2000 | A |
| 6011490 | Tonnesen et al. | Jan 2000 | A |
| 6020196 | Hu et al. | Feb 2000 | A |
| 6022306 | Dumont et al. | Feb 2000 | A |
| 6025201 | Zelmanovic et al. | Feb 2000 | A |
| 6027655 | Holm | Feb 2000 | A |
| 6049026 | Muschler | Apr 2000 | A |
| 6051146 | Green et al. | Apr 2000 | A |
| 6051147 | Bischof | Apr 2000 | A |
| 6053856 | Hlavinka | Apr 2000 | A |
| 6054122 | MacPhee et al. | Apr 2000 | A |
| 6063297 | Antanavich et al. | May 2000 | A |
| 6063624 | Kandler et al. | May 2000 | A |
| 6071421 | Brown | Jun 2000 | A |
| 6071422 | Hlavinka et al. | Jun 2000 | A |
| 6071423 | Brown et al. | Jun 2000 | A |
| 6090793 | Zimmermann et al. | Jul 2000 | A |
| 6096309 | Prior et al. | Aug 2000 | A |
| 6096728 | Collins et al. | Aug 2000 | A |
| 6102843 | Kelley et al. | Aug 2000 | A |
| 6117425 | Macphee et al. | Sep 2000 | A |
| 6123655 | Fell | Sep 2000 | A |
| 6150163 | McPherson et al. | Nov 2000 | A |
| 6153113 | Goodrich et al. | Nov 2000 | A |
| 6183737 | Zaleske et al. | Feb 2001 | B1 |
| 6196987 | Holmes et al. | Mar 2001 | B1 |
| 6197325 | Macphee et al. | Mar 2001 | B1 |
| 6200287 | Keller et al. | Mar 2001 | B1 |
| 6200606 | Peterson et al. | Mar 2001 | B1 |
| 6214338 | Antanavich et al. | Apr 2001 | B1 |
| 6221315 | Giesler et al. | Apr 2001 | B1 |
| 6245900 | Yamasaki et al. | Jun 2001 | B1 |
| 6264890 | Boehringer et al. | Jul 2001 | B1 |
| 6274090 | Coelho et al. | Aug 2001 | B1 |
| 6277961 | Hock et al. | Aug 2001 | B1 |
| 6280400 | Niermann | Aug 2001 | B1 |
| 6286670 | Smith | Sep 2001 | B1 |
| 6287558 | Lanza et al. | Sep 2001 | B1 |
| 6296602 | Headley | Oct 2001 | B1 |
| 6316247 | Katz et al. | Nov 2001 | B1 |
| 6322785 | Landesberg et al. | Nov 2001 | B1 |
| 6327491 | Franklin et al. | Dec 2001 | B1 |
| 6328765 | Hardwick et al. | Dec 2001 | B1 |
| 6334842 | Hlavinka et al. | Jan 2002 | B1 |
| 6337072 | Ford et al. | Jan 2002 | B1 |
| 6342157 | Hood, III | Jan 2002 | B1 |
| 6351659 | Vilsmeier | Feb 2002 | B1 |
| 6355239 | Bruder et al. | Mar 2002 | B1 |
| 6368298 | Beretta et al. | Apr 2002 | B1 |
| 6368498 | Guilmette | Apr 2002 | B1 |
| 6398972 | Blasetti et al. | Jun 2002 | B1 |
| 6406671 | Dicesare et al. | Jun 2002 | B1 |
| 6409528 | Bodnar | Jun 2002 | B1 |
| 6410344 | Chung | Jun 2002 | B1 |
| 6417004 | Brady et al. | Jul 2002 | B1 |
| 6440444 | Boyce et al. | Aug 2002 | B2 |
| 6444228 | Baugh et al. | Sep 2002 | B1 |
| 6464624 | Pages | Oct 2002 | B2 |
| 6471069 | Lin et al. | Oct 2002 | B2 |
| 6472162 | Coelho et al. | Oct 2002 | B1 |
| 6487992 | Hollis | Dec 2002 | B1 |
| 6508778 | Verkaart et al. | Jan 2003 | B1 |
| 6516953 | Dicesare et al. | Feb 2003 | B1 |
| 6523698 | Dennehey et al. | Feb 2003 | B1 |
| 6544162 | Van et al. | Apr 2003 | B1 |
| 6544727 | Hei | Apr 2003 | B1 |
| 6558341 | Swisher | May 2003 | B1 |
| 6563953 | Lin et al. | May 2003 | B2 |
| 6596180 | Baugh et al. | Jul 2003 | B2 |
| 6599873 | Sommer et al. | Jul 2003 | B1 |
| 6623472 | Reincke et al. | Sep 2003 | B1 |
| 6623959 | Harris | Sep 2003 | B2 |
| 6629919 | Egozy et al. | Oct 2003 | B2 |
| 6638503 | Chitte | Oct 2003 | B2 |
| 6641708 | Becker | Nov 2003 | B1 |
| 6649072 | Brandt et al. | Nov 2003 | B2 |
| 6676629 | Andrew et al. | Jan 2004 | B2 |
| 6713246 | Reinecke et al. | Mar 2004 | B1 |
| 6716187 | Jorgensen | Apr 2004 | B1 |
| 6719901 | Dolecek et al. | Apr 2004 | B2 |
| 6733471 | Ericson et al. | May 2004 | B1 |
| 6758978 | Bedell | Jul 2004 | B1 |
| 6759188 | Reinecke et al. | Jul 2004 | B2 |
| 6764531 | Hogan | Jul 2004 | B2 |
| 6777231 | Katz et al. | Aug 2004 | B1 |
| 6790371 | Dolecek | Sep 2004 | B2 |
| 6803022 | Dicesare et al. | Oct 2004 | B2 |
| 6811777 | Mishra | Nov 2004 | B2 |
| 6830762 | Baugh et al. | Dec 2004 | B2 |
| 6835353 | Smith et al. | Dec 2004 | B2 |
| 6835377 | Goldberg et al. | Dec 2004 | B2 |
| RE38730 | Jakary et al. | Apr 2005 | E |
| 6899813 | Dolecek et al. | May 2005 | B2 |
| 6905612 | Dorian et al. | Jun 2005 | B2 |
| 6911202 | Amir et al. | Jun 2005 | B2 |
| RE38757 | Jakary et al. | Jul 2005 | E |
| 6979307 | Beretta et al. | Dec 2005 | B2 |
| 7011644 | Andrew et al. | Mar 2006 | B1 |
| 7011852 | Sukavaneshvar et al. | Mar 2006 | B2 |
| 7077273 | Ellsworth et al. | Jul 2006 | B2 |
| 7077827 | Greenfield | Jul 2006 | B2 |
| 7155288 | Soykan et al. | Dec 2006 | B2 |
| 7166283 | Tsuji et al. | Jan 2007 | B2 |
| 7179391 | Leach et al. | Feb 2007 | B2 |
| 7195606 | Ballin | Mar 2007 | B2 |
| 7223346 | Dorian et al. | May 2007 | B2 |
| 7273886 | Olivero | Sep 2007 | B2 |
| 7302882 | Reuter | Dec 2007 | B2 |
| 7354515 | Coull et al. | Apr 2008 | B2 |
| 7374678 | Leach et al. | May 2008 | B2 |
| 7411006 | Shanbrom | Aug 2008 | B2 |
| 7465293 | Reinecke et al. | Dec 2008 | B2 |
| 7470371 | Dorian et al. | Dec 2008 | B2 |
| 7531355 | Rodríguez et al. | May 2009 | B2 |
| 7553413 | Dorian et al. | Jun 2009 | B2 |
| 7608258 | Mishra | Oct 2009 | B2 |
| 7678385 | Reddi | Mar 2010 | B2 |
| 7694828 | Swift et al. | Apr 2010 | B2 |
| 7708152 | Dorian et al. | May 2010 | B2 |
| 7806276 | Leach et al. | Oct 2010 | B2 |
| 7845499 | Higgins et al. | Dec 2010 | B2 |
| 7867765 | Faustman et al. | Jan 2011 | B2 |
| 7901344 | Yoo | Mar 2011 | B2 |
| 7901584 | Dorian et al. | Mar 2011 | B2 |
| 7914689 | Higgins et al. | Mar 2011 | B2 |
| 7987995 | Dorian et al. | Aug 2011 | B2 |
| 7992725 | Leach et al. | Aug 2011 | B2 |
| 8048297 | Leach et al. | Nov 2011 | B2 |
| 8048321 | Leach et al. | Nov 2011 | B2 |
| 8062534 | Higgins et al. | Nov 2011 | B2 |
| 8067534 | Jagota | Nov 2011 | B2 |
| 8093211 | Tennenbaum et al. | Jan 2012 | B2 |
| 8202539 | Behnam et al. | Jun 2012 | B2 |
| 8567609 | Landrigan et al. | Oct 2013 | B2 |
| 8596470 | Leach et al. | Dec 2013 | B2 |
| 8753690 | Higgins et al. | Jun 2014 | B2 |
| 8783470 | Hecker et al. | Jul 2014 | B2 |
| 8801586 | Dorian et al. | Aug 2014 | B2 |
| 8808551 | Leach et al. | Aug 2014 | B2 |
| 8950586 | Dorian et al. | Feb 2015 | B2 |
| 8992862 | Leach et al. | Mar 2015 | B2 |
| 9011800 | Leach et al. | Apr 2015 | B2 |
| 9119829 | Higgins et al. | Sep 2015 | B2 |
| 9308224 | Higgins et al. | Apr 2016 | B2 |
| 9556243 | Leach et al. | Jan 2017 | B2 |
| 9701728 | Higgins et al. | Jul 2017 | B2 |
| 9758806 | Woodell-May et al. | Sep 2017 | B2 |
| 9763875 | Higgins et al. | Sep 2017 | B2 |
| 9878011 | Landrigan et al. | Jan 2018 | B2 |
| 9895418 | Landrigan et al. | Feb 2018 | B2 |
| 20010009757 | Bischof et al. | Jul 2001 | A1 |
| 20010016195 | Tobinick | Aug 2001 | A1 |
| 20010053764 | Sims et al. | Dec 2001 | A1 |
| 20020009454 | Boone et al. | Jan 2002 | A1 |
| 20020032112 | Pages | Mar 2002 | A1 |
| 20020035820 | Farris | Mar 2002 | A1 |
| 20020076400 | Katz et al. | Jun 2002 | A1 |
| 20020077276 | Fredeking et al. | Jun 2002 | A1 |
| 20020082220 | Hoemann et al. | Jun 2002 | A1 |
| 20020090711 | Karlsson | Jul 2002 | A1 |
| 20020104808 | Blasetti et al. | Aug 2002 | A1 |
| 20020114775 | Pathak | Aug 2002 | A1 |
| 20020119179 | Rezania et al. | Aug 2002 | A1 |
| 20020161449 | Muschler | Oct 2002 | A1 |
| 20020169408 | Beretta et al. | Nov 2002 | A1 |
| 20020172666 | Sacchi et al. | Nov 2002 | A1 |
| 20020182664 | Dolecek et al. | Dec 2002 | A1 |
| 20020192632 | Hei et al. | Dec 2002 | A1 |
| 20030033021 | Plouhar et al. | Feb 2003 | A1 |
| 20030033022 | Plouhar et al. | Feb 2003 | A1 |
| 20030050709 | Noth et al. | Mar 2003 | A1 |
| 20030050710 | Petersen et al. | Mar 2003 | A1 |
| 20030055511 | Schryver et al. | Mar 2003 | A1 |
| 20030082152 | Hedrick et al. | May 2003 | A1 |
| 20030091536 | Frisbie et al. | May 2003 | A1 |
| 20030099650 | Ho et al. | May 2003 | A1 |
| 20030138910 | Reinecke et al. | Jul 2003 | A1 |
| 20030185803 | Kadiyala et al. | Oct 2003 | A1 |
| 20030191429 | Andrew et al. | Oct 2003 | A1 |
| 20030194397 | Mishra | Oct 2003 | A1 |
| 20030205538 | Dorian et al. | Nov 2003 | A1 |
| 20040005246 | Efthimiadis et al. | Jan 2004 | A1 |
| 20040013575 | Stevens et al. | Jan 2004 | A1 |
| 20040120942 | McGinnis et al. | Jun 2004 | A1 |
| 20040171146 | Katz et al. | Sep 2004 | A1 |
| 20040182395 | Brookman | Sep 2004 | A1 |
| 20040182788 | Dorian et al. | Sep 2004 | A1 |
| 20040182795 | Dorian et al. | Sep 2004 | A1 |
| 20040219182 | Gomes et al. | Nov 2004 | A1 |
| 20040251217 | Leach et al. | Dec 2004 | A1 |
| 20040258671 | Watkins | Dec 2004 | A1 |
| 20050059589 | Mullarkey | Mar 2005 | A1 |
| 20050076396 | Katz et al. | Apr 2005 | A1 |
| 20050084961 | Hedrick et al. | Apr 2005 | A1 |
| 20050084962 | Simon | Apr 2005 | A1 |
| 20050100536 | Mishra | May 2005 | A1 |
| 20050109716 | Leach et al. | May 2005 | A1 |
| 20050130301 | Mckay et al. | Jun 2005 | A1 |
| 20050145187 | Gray | Jul 2005 | A1 |
| 20050152905 | Omoigui | Jul 2005 | A1 |
| 20050153441 | Hedrick et al. | Jul 2005 | A1 |
| 20050153442 | Katz et al. | Jul 2005 | A1 |
| 20050186120 | Dorian et al. | Aug 2005 | A1 |
| 20050196393 | Shanbrom | Sep 2005 | A1 |
| 20050196874 | Dorian et al. | Sep 2005 | A1 |
| 20050197293 | Mellis et al. | Sep 2005 | A1 |
| 20050247715 | Ellsworth et al. | Nov 2005 | A1 |
| 20050260174 | Fraser et al. | Nov 2005 | A1 |
| 20050260175 | Hedrick et al. | Nov 2005 | A1 |
| 20050282275 | Katz et al. | Dec 2005 | A1 |
| 20060046960 | McKay et al. | Mar 2006 | A1 |
| 20060051865 | Higgins et al. | Mar 2006 | A1 |
| 20060057223 | DiMauro et al. | Mar 2006 | A1 |
| 20060057693 | Simon | Mar 2006 | A1 |
| 20060083720 | Fraser et al. | Apr 2006 | A1 |
| 20060121002 | Rolland et al. | Jun 2006 | A1 |
| 20060140923 | Evangelista | Jun 2006 | A1 |
| 20060151384 | Ellsworth et al. | Jul 2006 | A1 |
| 20060171948 | Weinstein et al. | Aug 2006 | A1 |
| 20060175242 | Dorian et al. | Aug 2006 | A1 |
| 20060175244 | Dorian et al. | Aug 2006 | A1 |
| 20060175268 | Dorian et al. | Aug 2006 | A1 |
| 20060178610 | Nowakowski | Aug 2006 | A1 |
| 20060196885 | Leach et al. | Sep 2006 | A1 |
| 20060243676 | Swift et al. | Nov 2006 | A1 |
| 20060263408 | Rezania et al. | Nov 2006 | A1 |
| 20060273049 | Leach et al. | Dec 2006 | A1 |
| 20060273050 | Higgins et al. | Dec 2006 | A1 |
| 20060278588 | Woodell-May | Dec 2006 | A1 |
| 20070027082 | Hasty et al. | Feb 2007 | A1 |
| 20070034579 | Dorian et al. | Feb 2007 | A1 |
| 20070036768 | Fraser et al. | Feb 2007 | A1 |
| 20070075016 | Leach | Apr 2007 | A1 |
| 20070092494 | Higgins et al. | Apr 2007 | A1 |
| 20070207161 | Ralph | Sep 2007 | A1 |
| 20070208321 | Leach et al. | Sep 2007 | A1 |
| 20080011684 | Dorian et al. | Jan 2008 | A1 |
| 20080019964 | Olmarker et al. | Jan 2008 | A1 |
| 20080064626 | Zanella | Mar 2008 | A1 |
| 20080164204 | Hatamian et al. | Jul 2008 | A1 |
| 20080173593 | Coull et al. | Jul 2008 | A1 |
| 20080193424 | McKale et al. | Aug 2008 | A1 |
| 20080217263 | Higgins et al. | Sep 2008 | A1 |
| 20080217264 | Leach et al. | Sep 2008 | A1 |
| 20080217265 | Leach et al. | Sep 2008 | A1 |
| 20080268064 | Woodell-May | Oct 2008 | A1 |
| 20080269762 | Simon et al. | Oct 2008 | A1 |
| 20080283474 | Leach et al. | Nov 2008 | A1 |
| 20080306431 | Yoo | Dec 2008 | A1 |
| 20080318317 | Roche et al. | Dec 2008 | A1 |
| 20090014391 | Leach et al. | Jan 2009 | A1 |
| 20090018313 | Shanbrom | Jan 2009 | A1 |
| 20090047242 | Reinecke et al. | Feb 2009 | A1 |
| 20090101599 | Dorian et al. | Apr 2009 | A1 |
| 20090112146 | Wratten et al. | Apr 2009 | A1 |
| 20090181019 | Solinger | Jul 2009 | A1 |
| 20090191217 | de Wildt et al. | Jul 2009 | A1 |
| 20090192528 | Higgins et al. | Jul 2009 | A1 |
| 20090220482 | Higgins | Sep 2009 | A1 |
| 20090221075 | Dorian et al. | Sep 2009 | A1 |
| 20090236297 | Dorian et al. | Sep 2009 | A1 |
| 20090250413 | Hoeppner | Oct 2009 | A1 |
| 20090253566 | Chavarria | Oct 2009 | A1 |
| 20090263319 | Wohabrebbi et al. | Oct 2009 | A1 |
| 20090289014 | Hoeppner | Nov 2009 | A1 |
| 20090317439 | Turzi et al. | Dec 2009 | A1 |
| 20100008992 | Ichim | Jan 2010 | A1 |
| 20100015129 | Abramson et al. | Jan 2010 | A1 |
| 20100055087 | Higgins et al. | Mar 2010 | A1 |
| 20100125236 | Bare et al. | May 2010 | A1 |
| 20100140182 | Chapman et al. | Jun 2010 | A1 |
| 20100186676 | Van Der | Jul 2010 | A1 |
| 20100198130 | Swift et al. | Aug 2010 | A1 |
| 20100206798 | Dorian et al. | Aug 2010 | A1 |
| 20100226909 | Hecker et al. | Sep 2010 | A1 |
| 20100256595 | Leach et al. | Oct 2010 | A1 |
| 20100323870 | Leach et al. | Dec 2010 | A1 |
| 20100324450 | Leach et al. | Dec 2010 | A1 |
| 20110014705 | Leach et al. | Jan 2011 | A1 |
| 20110020196 | Grippi et al. | Jan 2011 | A1 |
| 20110021334 | Leach et al. | Jan 2011 | A1 |
| 20110036786 | Ellsworth | Feb 2011 | A1 |
| 20110052561 | Hoeppner | Mar 2011 | A1 |
| 20110056893 | Leach et al. | Mar 2011 | A1 |
| 20110059082 | Germer et al. | Mar 2011 | A1 |
| 20110059083 | Aigner et al. | Mar 2011 | A1 |
| 20110059084 | Osterroth et al. | Mar 2011 | A1 |
| 20110065183 | Dorian et al. | Mar 2011 | A1 |
| 20110077596 | Higgins et al. | Mar 2011 | A1 |
| 20110129441 | Lentz | Jun 2011 | A1 |
| 20110168193 | Leach et al. | Jul 2011 | A1 |
| 20110189172 | Solinger et al. | Aug 2011 | A1 |
| 20110192804 | Landrigan et al. | Aug 2011 | A1 |
| 20110251041 | Chavarria et al. | Oct 2011 | A1 |
| 20110268708 | Lin et al. | Nov 2011 | A1 |
| 20110300102 | Chung et al. | Dec 2011 | A1 |
| 20120010559 | Higgins et al. | Jan 2012 | A1 |
| 20120015796 | Leach et al. | Jan 2012 | A1 |
| 20120027746 | Dorian et al. | Feb 2012 | A1 |
| 20120093936 | Lindenberg et al. | Apr 2012 | A1 |
| 20120145652 | Leach et al. | Jun 2012 | A1 |
| 20120150086 | Cohen | Jun 2012 | A1 |
| 20120172836 | Higgins et al. | Jul 2012 | A1 |
| 20120228203 | Hecker et al. | Sep 2012 | A1 |
| 20130068676 | Leach et al. | Mar 2013 | A1 |
| 20130102452 | Leach et al. | Apr 2013 | A1 |
| 20130178425 | Higgins et al. | Jul 2013 | A1 |
| 20130196425 | Dorian et al. | Aug 2013 | A1 |
| 20130259951 | O'Connell, Jr. | Oct 2013 | A1 |
| 20130294983 | Dorian et al. | Nov 2013 | A1 |
| 20140051061 | Landrigan et al. | Feb 2014 | A1 |
| 20140054246 | Landrigan et al. | Feb 2014 | A1 |
| 20140091048 | Leach et al. | Apr 2014 | A1 |
| 20140242045 | Higgins et al. | Aug 2014 | A1 |
| 20140271587 | Landrigan et al. | Sep 2014 | A1 |
| 20140271588 | Landrigan et al. | Sep 2014 | A1 |
| 20140271589 | Matuska et al. | Sep 2014 | A1 |
| 20140271870 | O'Shaughnessey et al. | Sep 2014 | A1 |
| 20140274893 | Woodell-May et al. | Sep 2014 | A1 |
| 20140274895 | Binder et al. | Sep 2014 | A1 |
| 20140275497 | Leach et al. | Sep 2014 | A1 |
| 20140349388 | Dorian et al. | Nov 2014 | A1 |
| 20140356446 | Leach et al. | Dec 2014 | A1 |
| 20150141332 | Toler | May 2015 | A1 |
| 20150147300 | Woodell-May et al. | May 2015 | A1 |
| 20160000870 | Higgins et al. | Jan 2016 | A1 |
| 20160017010 | Higgins et al. | Jan 2016 | A1 |
| 20160074479 | Serbousek et al. | Mar 2016 | A1 |
| 20160136245 | Toler et al. | May 2016 | A1 |
| 20160166645 | Matuska et al. | Jun 2016 | A1 |
| 20170334960 | Higgins et al. | Nov 2017 | A1 |
| 20180099026 | Landrigan et al. | Apr 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 696278 | Sep 1998 | AU |
| 748575 | Jun 2002 | AU |
| 9103724 | Mar 1993 | BR |
| 1321138 | Aug 1993 | CA |
| 2182862 | Jun 1996 | CA |
| 2448415 | Dec 2002 | CA |
| 2772084 | Oct 2016 | CA |
| 1074709 | Jul 1993 | CN |
| 1321103 | Nov 2001 | CN |
| 1322146 | Nov 2001 | CN |
| 103702729 | Apr 2014 | CN |
| 105209478 | Dec 2015 | CN |
| 105338990 | Feb 2016 | CN |
| 105339007 | Feb 2016 | CN |
| 105358161 | Feb 2016 | CN |
| 105492015 | Apr 2016 | CN |
| 56103 | Oct 1960 | DE |
| 1443359 | Nov 1968 | DE |
| 4202667 | May 1993 | DE |
| 090997 | Oct 1983 | EP |
| 0102773 | Mar 1984 | EP |
| 0109374 | May 1984 | EP |
| 0142339 | May 1985 | EP |
| 0244834 | Nov 1987 | EP |
| 0253198 | Jan 1988 | EP |
| 0295771 | Dec 1988 | EP |
| 0417818 | Mar 1991 | EP |
| 0534178 | Mar 1993 | EP |
| 0592242 | Apr 1994 | EP |
| 1005910 | Jun 2000 | EP |
| 1006360 | Jun 2000 | EP |
| 1289618 | Mar 2003 | EP |
| 1427279 | Jun 2004 | EP |
| 1467746 | Oct 2004 | EP |
| 1509326 | Mar 2005 | EP |
| 1652538 | May 2006 | EP |
| 1670315 | Jun 2006 | EP |
| 1716901 | Nov 2006 | EP |
| 1406492 | Dec 2009 | EP |
| 2186877 | May 2010 | EP |
| 2968409 | Jan 2016 | EP |
| 2968412 | Jan 2016 | EP |
| 2470163 | Sep 2016 | EP |
| 854715 | Nov 1960 | GB |
| 60053845 | Mar 1985 | JP |
| 60250014 | Dec 1985 | JP |
| 2036872 | Feb 1990 | JP |
| 02071747 | Mar 1990 | JP |
| 02129224 | May 1990 | JP |
| 069684 | Jan 1994 | JP |
| 07101874 | Apr 1995 | JP |
| 2002509529 | Mar 2000 | JP |
| 2000189407 | Jul 2000 | JP |
| 2000199760 | Jul 2000 | JP |
| 2003525696 | Sep 2003 | JP |
| 2004305439 | Nov 2004 | JP |
| 2005013783 | Jan 2005 | JP |
| 2005098704 | Apr 2005 | JP |
| 2005524451 | Aug 2005 | JP |
| 2006305365 | Nov 2006 | JP |
| 2006527025 | Nov 2006 | JP |
| 2007105186 | Apr 2007 | JP |
| 2007509601 | Apr 2007 | JP |
| 2008104789 | May 2008 | JP |
| 2009155234 | Jul 2009 | JP |
| 5551250 | Jul 2014 | JP |
| WO-8400905 | Mar 1984 | WO |
| WO-8802259 | Apr 1988 | WO |
| WO-9010031 | Sep 1990 | WO |
| WO9222312 | Dec 1992 | WO |
| WO-9305067 | Mar 1993 | WO |
| WO-9308904 | May 1993 | WO |
| WO-9407548 | Apr 1994 | WO |
| WO-9617871 | Jun 1996 | WO |
| WO-1998024477 | Jun 1998 | WO |
| WO-9848938 | Nov 1998 | WO |
| 9905989 | Feb 1999 | WO |
| 9967277 | Dec 1999 | WO |
| WO-0061256 | Oct 2000 | WO |
| WO-0074713 | Dec 2000 | WO |
| WO-0103756 | Jan 2001 | WO |
| WO-0183068 | Nov 2001 | WO |
| WO-0238610 | May 2002 | WO |
| WO-02060925 | Aug 2002 | WO |
| WO-02098566 | Dec 2002 | WO |
| WO-03015800 | Feb 2003 | WO |
| WO-03024215 | Mar 2003 | WO |
| WO-03053362 | Jul 2003 | WO |
| 03063799 | Aug 2003 | WO |
| 03080104 | Oct 2003 | WO |
| 03088905 | Oct 2003 | WO |
| WO-03092894 | Nov 2003 | WO |
| WO-03099412 | Dec 2003 | WO |
| 2004009207 | Jan 2004 | WO |
| WO-2004065564 | Aug 2004 | WO |
| WO-2004104553 | Dec 2004 | WO |
| WO-2005034843 | Apr 2005 | WO |
| 2006043972 | Apr 2006 | WO |
| WO-2006041406 | Apr 2006 | WO |
| 2007121538 | Nov 2007 | WO |
| 2007128973 | Nov 2007 | WO |
| WO-2007127834 | Nov 2007 | WO |
| WO-2007142908 | Dec 2007 | WO |
| 2008021237 | Feb 2008 | WO |
| WO-2008127639 | Oct 2008 | WO |
| WO-2009021257 | Feb 2009 | WO |
| WO-2009108890 | Sep 2009 | WO |
| WO-2009111338 | Sep 2009 | WO |
| WO-2010115190 | Oct 2010 | WO |
| WO-2010149164 | Dec 2010 | WO |
| WO-2011008836 | Jan 2011 | WO |
| 2011031553 | Mar 2011 | WO |
| WO-2011031524 | Mar 2011 | WO |
| WO-2011031524 | Mar 2011 | WO |
| WO-2011031525 | Mar 2011 | WO |
| 2012030593 | Mar 2012 | WO |
| WO 2012030593 | Mar 2012 | WO |
| WO2012030593 | Mar 2012 | WO |
| WO-2012030593 | Mar 2012 | WO |
| WO-2014144505 | Sep 2014 | WO |
| WO-2014144505 | Sep 2014 | WO |
| WO-2015099684 | Jul 2015 | WO |
| Entry |
|---|
| Wang et al. Cell separation by dielectrophoretic field-flow-fractionation. Analytical Chemistry. 2000; 72(4): 832-839. |
| Pommer et al. Dielectrophoretic separation of platelets from whole blood in microfluidic channels. Electrophoresis. 2008; 29:1213-1218. |
| Alford, J. et al. “Cartilage Restoration, Part 1” The American Journal of Sports Medicine, vol. 33, No. 2 (2005) p. 295-306. |
| Anitua, E. et al. “Autologous platelets as a source of proteins for healing and tissue regeneration” Thromb Haemost, vol. 91 (pp. 4-15) 2004. |
| Anonymous: “Update for veterinarians” Dec. 2012. vet.osu.edu/sites/default/files/documents/pdf/news/vmc/ovmaVeternarianUp/date/20121112.pdf. |
| Arend, W. et al. “Interleukin-1 Receptor Antagonist: Role in Biology” Annu. Rev. Immunol., vol. 16 (pp. 27-55) 1998. |
| Baltzer AW, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage Feb. 1, 2009; 17(2):152-60. |
| Becker C. et al. Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an Investigator-initiated, prospective, double-blind, reference-controlled study. Spine Aug. 1, 2007; 32(17):1803-8. |
| Bendele et al. “Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis” Arthritis & Rheumatism, vol. 43, No. 12, Dec. 2000, pp. 2648-2659. |
| Bielecki, T. et al, “Antibacterial effect of autologous platelet gel enriched with growth factors and toher acive substances” J Bone Joint Surg, vol. 89-B, No. 3 (p. 417-420) Mar. 2007. |
| Bio-Rad Laboratories. Bio-Gel P Polyacrylamide Gel Instruction Manual, Obtained from www.bio-rad.com/webmaster/pdfs/9154_Bio-Gel_P.pdf on Jun. 20, 2012 (14 pages). |
| Biomet Biologics, Inc. “GPS® II Platelet Concentrate System: The New Gold Standard” Product Brochure (14 pages) Sep. 2006. |
| Biomet Biologics, Inc. “GPS® III Platelet Separation System” Product Brochure (8 pages) 2007. |
| Biomet Biologics, Inc. “Plasmax Plasma Concentrate” Product Brochure (6 pages) 2006. |
| Biomet Biologics, Inc. “Vortech Concentration System Product” Product Brochure (16 pages) Aug. 2005. |
| Biomet Biologics, Inc. “GPS System Shoulder Recovery with the GPS Platelet Concentrate System” Product Brochure (6 pages) 2004. |
| Burnouf, T. “Blood-derived, tissue engineering biomaterials” Biomedical Engineering-Applications, Basis & Communications, vol. 16, No. 6, Dec. 2004 (pp. 294-304). |
| Cell Factor Technologies, Inc. “GPS® Platelet Concentrate System” Product Brochure (9 pages) 2004. |
| Cell Factor Technologies, Inc., Biomet Europe. “GPS® II System, Gravitational Platelet Separation System” User Manual (13 pages), http://www.cellfactortech.com/global_products.cfm, printed Sep. 16, 2005. |
| Cell Factor Technologies, Inc., Biomet Europe. “GPS® II System, Gravitational Platelet Separation System, Accelerating the Body's Natural Healing Process” Product Bruchure (16 pages) 2005. |
| Dallari et al. “Enhanced Tibial Osteotomy Healing with Use of Bone Grafts Supplemented with Platelet Gel or Platelet Gel and Bone Marrow Stromal Cells” The Journal of Bone and Joint Surgery, vol. 89 (2007) pp. 2413-2420. |
| Dinarello, C. “Interleukin-1 and Interleukin-1 Antagonism” Blood, vol. 77, No. 8 (pp. 1627-1652) Apr. 1991. |
| Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011, vol. 117 (14), p. 3720-3732. |
| Eppley, et al. “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004). |
| Evans, C.H.Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs 2005; 19(6):355-62. |
| Fiotti et al. “Atherosclerosis and Inflammation. Patterns of Cytokine Regulation in Patients with Peripheral Arterial Disease” Atherosclerosis, Elsevier Ireland Ltd, IE, vol. 145, No. 1, pp. 51-60. Jul. 1, 1999. |
| Floryan, K. et al. “Home Study Program: Intraoperative use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674. |
| Hou, WH et al. “Microfluidic Devices for Blood Fractionation” Micromachines (2011) 2, 319-343. |
| Juge-Aubry, C. et al. “Adipose Tissue is a Major Source of Interleukin-1 Receptor Antagonist” Diabetes, vol. 52, May 2003 (pp. 1104-1110). |
| Kaufman, A. et al. “Human macrophage response to UHMWPE, TiAIV, CoCr, and alumina particles: Analysis of multiple cytokines using protein arrays” Journal of Biomedical Materials Research Part A, published online in Wiley InterScience DOI: 10.1002/jbm.a.31467 (pp. 464-474) Jul. 2007. |
| Kim, Seon Hee et al. “Ex vivo gene delivery of Il-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis”, Molecular Therapy, vol. 6, No. 5, Nov. 1, 2002 (pp. 591-600). |
| King, W. et al. “A simple method to Correlate the Concentration of an Anti-Inflammatory Cytokine with White Blood Cells in an Autologous Protein Solution” Feb. 24, 2014. |
| Klingenberg et al. “Treating inflammation in Atherosclerotic Cardiovascular Disease: Emerging Therapies” European Heart Journal., vol. 30, No. 23, pp. 2838-2844, Dec. 2009. |
| Lavi, G. et al. “Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases” Journal of Controlled Release. 123, 123-130 (2007). |
| Lucarelli, E. et al. “Platelet-derived growth factors enhance proliferation of human stromal stem cells” Biomaterials, vol. 24 (2003) pp. 3095-3100. |
| Matthews, J. et al. “Comparison of the response of primary human peripheral blood mononuclear phagocytes from different donors to challenge with model polyethylene particles of known size and dose” Biomaterials, vol. 21 (pp. 2033-2044) 2000. |
| Meijer, H. et al. “The production of antiinflammatory cytokines in whole blood by physico-chemical induction” Inflamm. Res., vol. 52 (pp. 404-407) Oct. 2003. |
| Miltenyi Biotec GmbH, Isolation of Granulocytes From Human Peripheral Blood by Density Gradient Centrifugation (2008) 2 pages. |
| Morizaki et al. “The Effects of Platelet-Rich Plasma on Bone Marrow Stromal Cell Transplants for Tendon Healing in Vitro” J. Hand Surg. Am., vol. 35, No. 11 (Nov. 2010) pp. 1833-1841. |
| Murphy et al. “Autologous Bone Marrow Mononuclear Cell Therapy is Safe and Promotes Amputation-free Survival in Patients with Critical Limb Ischemia” Journal of Vascular Surgery, C.V. Mosby Co., vol. 53, No. 6, Jan. 28, 2011. |
| Muzio, M. et al. “Interleukin-13 Induces the Production of Interleukin-1 Receptor Antagonist (IL-1ra) and the Expression of the mRNA for the Intracellular (Keratinocyte) Form of IL-1ra in Human Myelomonocytic Cells” Blood, vol. 83, No. 7 (pp. 1738-1743) Apr. 1994. |
| Nursen Düzgün et al. “Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease” Rheumatology International ; Clinical and Experimental Investigations, Springer, Berlin, DE vol. 25, No. 1, Jan. 2005. p. 1-5. |
| O'Shaughnessey, K.M. et al. Blood-derived anti-inflammatory protein solution blocks the effect of IL-1beta on human macrophages in vitro. Inflamm Res Oct. 2011; 60(10):929-36. |
| Plasmax® Plasma Concentration System. 2007. Biomet Biologics. p. 1-20. |
| Rader, C. et al. “Cytokine Response of Human Macrophage-like Cells After Contact With Polyethylene and Pure Titanium Particles” The Journal of Arthroplasty, vol. 14, No. 7 pp. 840-848 (Oct. 1999). |
| Sorbera L A “Pegsunercept. Pegylated Soluble Tumor Necrosis Factor Receptor Type 1 PEG-STNF-RI” Drugs of the Future, Prous Science, ES, vol. 28, No. 12. Jan. 1, 2003. p. 1182-1188. |
| Swift, M. et al. “Characterization of Growth Factors in Platelet Rich Plasma” Cell Factor Technologies, Inc. Printed Sep. 16, 2005 from www.cellfactortech.com/global_products.cfm. |
| Tateishi-Yuyama, E. et al. “Therapuetic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-barrow cells: a pilot study and randomised controlled trial” The Lancet 2002; 360:427-435. |
| Ulich, T.R. et al. “Intratrachael Administration of Endotoxin and Cytokines: IV. The Soluble Tumor Necrosis Factor Receptor Type 1 Inhibits Acute Inflammation” American Journal of Pathology; vol. 142, No. 5, May 1993. |
| Vangsness, T. et al. “Stimulation of IL-1ra Production from Platelet-Rich Plasma” Poster No. 488 presented at 54th Annual Meeting of the Orthopeadic Research Society in San Francisco, CA (1 page) Mar. 2-5, 2008. |
| Woodell-May, J. et al. “Effect of Incubation Time on Production of IL-1ra and sTNF-RI from Platelet-Rich Plasma” Paper No. 200, 55th Annual Meeting of the Orthopaedic Research Society (1 page) Feb. 2009. |
| Woodell-May, J. et al. “Elution of IL-1ra from a concentrated-plasma matrix—An in vitro study” Poster Presentation at 8th World Congress of the International Cartilage Repair Society, Miami, FL. (1 page) May 2009. |
| “U.S. Appl. No. 12/394,723, Response filed Mar. 6, 2017 to Non Final Office Action dated Oct. 5, 2016”, 25 pgs. |
| “U.S. Appl. No. 13/392,266, Notice of Allowance dated Mar. 6, 2017”, 8 pgs. |
| “U.S. Appl. No. 13/392,266, Response filed Jan. 4, 2017 to Non Final Office Action dated Oct. 4, 2016”, 22 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Dec. 22, 2016 to Advisory Action dated Dec. 2, 2016”, 10 pgs. |
| “U.S. Appl. No. 13/841,083, Examiner Interview dated Feb. 24, 2017”, 1 pg. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Feb. 24, 2017”, 12 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed Mar. 13, 2017 to Final Office Action dated Dec. 14, 2016”, 14 pgs. |
| “U.S. Appl. No. 14/803,414, Non Final Office Action dated Apr. 19, 2017”, 35 pgs. |
| “U.S. Appl. No. 14/803,414, Response filed Dec. 19, 2016 to Restriction Requirement dated Oct. 20, 2016”, 7 pgs. |
| “U.S. Appl. No. 14/808,828, Response filed Mar. 8, 2017 to Non Final Office Action dated Dec. 8, 2016”, 9 pgs. |
| “U.S. Appl. No. 14/830,977, Response filed Jan. 20, 2017 to Final Office Action dated Oct. 20, 2016”, 27 pgs. |
| “Application Serial No. 14709014.6, Response filed Feb. 27, 2017 to Non Final Office Action dated Oct. 20, 2016”, 22 pgs. |
| “Application Serial No. 14714491.9, Non Final Office Action dated Mar. 6, 2017”, 9 pgs. |
| “Canadian Application No. 2,810,202, Response filed Jan. 26, 2017 to Non Final Office Action dated Aug. 11, 2016”, 8 pgs. |
| “Canadian Application Serial No. 2,810,202, Office Action dated Aug. 11, 2016”, 4 pgs. |
| “Chinese Application Serial No. 201480027178.3, Voluntary Amendment filed Jul. 15, 2016”, w/English claims, 35 pgs. |
| “European Application No. 15184504.7, Response filed Jan. 25, 2017 to Non Final Office Action dated Sep. 16, 2016”, 10 pgs. |
| “European Application No. 10754613.7, Non Final Office Action dated Feb. 7, 2017”, 5 pgs. |
| “European Application Serial No. 14707069.2, Response Filed Mar. 27, 2017 to Communication Pursuant to Article 94(3) EPC dated Nov. 5, 2016”, 16 pgs. |
| “European Application Serial No. 14707909.9, Communication Pursuant to Article 94(3) EPC dated Dec. 16, 2016”, 5 pgs. |
| “European Application Serial No. 14714491.9, Communication Pursuant to Article 94(3) EPC dated Feb. 28, 2017”, 9 pgs. |
| “European Application Serial No. 15184504.7, Communication Pursuant to Article 94(3) EPC dated Feb. 13, 2016”, 5 pgs. |
| “European Application Serial No. 15184504.7, Communication Pursuant to Article 94(3) EPC dated Feb. 13, 2017”, 6 pgs. |
| Abegao, K., et al., “Effects of heterologous platelet-rich plasma gel on standardized dermal wound healing in rabbits”, Acta Cirurgica Brasileira—vol. 30(3), (2015), pp. 208-215. |
| Abramson, S. B., et al., “Blocking the effects o IL-1 in rheumatoid arthritis protects bone and cartilage”, Rheumatology; 41, (2002), 972-980 pgs. |
| Agu, R. U., et al., “The lung as a route for systemic delivery of therapeutic proteins and peptides”, Respir Res.; vol. 2, (2001), pp. 198-209. |
| Danis, V. A., et al., “Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-IRa) gene polymorphism”, Clin Exp Immunol; (99), (1995), p. 303-310. |
| Fini, M., et al., “Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies”, Biomed Pharmacother; vol. 59, (2005), pp. 388-394. |
| Greppi, N., et al., “Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients”, Biologicals. Academic Press Ltd. vol. 39. No. 2, (Jan. 6, 2011), 73-80 pgs. |
| Gullung, Gregory B., et al., “Platelet-rich plasma effects on degenerative disc disease: analysis of histology and imaging in an animal model”, Evidence-Based Spine-Care Journal, vol. 2, Issue 4, (2011), 13-18. |
| Ma, Chaoyong, “Animal Models of Disease: These systems are becoming increasingly important secondary screes of in vitro hits.”, Modern Drug Discovery, (Jun. 2004), pp. 30-36. |
| Obata, Shuji, et al., “Effect of autologous platelet-rich plasma-releasate on intervertebral disc degeneration in the rabbit anular puncture model: a preclinical study”, Arthritis Research & Therapy. vol. 14 http://arthritis-research.com/content/14/6/R241, (2012), 12 pgs. |
| Ravi Kumar, H. S., et al., “Autologous Conditioned Serum as a Novel Alternative Option in the Treatment of Unilateral Lumbar Radiculopathy: A Prospective Study”, Asian Spine Journal; 9(6), (2015), 916-922. |
| Sampson, Steven, et al., “Platelet rich plasma injection grafts for musculoskeletal injuries: a review”, Curr Rev Musculoskelet Med, vol. 1, (Jul. 16, 2008), 165-174. |
| Stankiewicz, W., et al., “Low energy electromagnetic fields and immunity”, Int. Rev. Allergol. Clin. Immunol, vol. 15, No. 1-2, (2009), pp. 36-41. |
| Xie, X., et al., “Biology of platelet-rich plasma and its clinical application in cartilage repair”, Arthritis Research & Therapy, 16:204, (2014), 15 pgs. |
| Zhang, et al., “Nanosecond pulse electric field (nanopulse): A novel non-ligand agonist for platelet activation”, Archives of Biochemistry and Biophysics, Academic Press, US, vol. 471, No. 2, (Dec. 23, 2007), 240-248. |
| “U.S. Appl. No. 12/101,586, Final Office Action dated Feb. 3, 2011”, 11 pgs. |
| “U.S. Appl. No. 12/101,586, Non Final Office Action dated Sep. 20, 2010”, 12 pgs. |
| “U.S. Appl. No. 12/101,586, Notice of Allowance dated Mar. 24, 2011”, 5 pgs. |
| “U.S. Appl. No. 12/101,594, Final Office Action dated Mar. 18, 2010”, 8 pgs. |
| “U.S. Appl. No. 12/101,594, Non Final Office Action dated Oct. 16, 2009”, 8 pgs. |
| “U.S. Appl. No. 12/101,594, Notice of Allowance dated May 27, 2010”, 7 pgs. |
| “U.S. Appl. No. 12/394,723, Appeal Brief filed Jun. 15, 2015”, 42 pgs. |
| “U.S. Appl. No. 12/394,723, Decision on Pre-Appeal Brief dated Feb. 13, 2015”, 2 pgs. |
| “U.S. Appl. No. 12/394,723, Examiner's Answer to Appeal Brief dated Sep. 9, 2015”, 11 pgs. |
| “U.S. Appl. No. 12/394,723, Final Office Action dated Apr. 19, 2016”, 13 pgs. |
| “U.S. Appl. No. 12/394,723, Non Final Office Action dated Dec. 24, 2015”, 9 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Jan. 8, 2015 to Pre-Appeal Brief Request dated Dec. 19, 2014”, 4 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Aug. 19, 2016 to Final Office Action dated Apr. 19, 2016”, 23 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Nov. 9, 2015 to Final Office Action dated Sep. 8, 2014”, 19 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Mar. 24, 2016 to Non Final Office Action dated Dec. 24, 2015”, 18 pgs. |
| “U.S. Appl. No. 12/549,116, Decision on Pre-Appeal Brief dated Feb. 5, 2015”, 2 pgs. |
| “U.S. Appl. No. 12/549,116, Final Office Action dated Jan. 4, 2016”, 15 pgs. |
| “U.S. Appl. No. 12/549,116, Non Final Office Action dated Jun. 4, 2015”, 12 pgs. |
| “U.S. Appl. No. 12/549,116, Pre-Appeal Brief Request filed Jan. 8, 2015”, 5 pgs. |
| “U.S. Appl. No. 12/549,116, Response filed Mar. 3, 2016 to Final Office Action dated Jan. 4, 2016”, 11 pgs. |
| “U.S. Appl. No. 12/549,116, Response filed Sep. 4, 2015 to Non Final Office Action dated Jun. 4, 2015”, 9 pgs. |
| “U.S. Appl. No. 12/897,401, Non Final Office Action dated Nov. 16, 2010”, 9 pgs. |
| “U.S. Appl. No. 12/897,401, Notice of Allowance dated Oct. 18, 2011”, 6 pgs. |
| “U.S. Appl. No. 13/392,266, Final Office Action dated Jul. 30, 2015”, 12 pgs. |
| “U.S. Appl. No. 13/392,266, Non Final Office Action dated Feb. 26, 2015”, 9 pgs. |
| “U.S. Appl. No. 13/392,266, Response filed Jan. 22, 2016 to Final Office Action dated Jul. 30, 2015”, 24 pgs. |
| “U.S. Appl. No. 13/392,266, Response filed Jul. 8, 2015 to Non-Final Office Action dated Feb. 26, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/782,421, Final Office Action dated Jan. 15, 2015”, 30 pgs. |
| “U.S. Appl. No. 13/782,421, Notice of Allowance dated Apr. 27, 2015”, 8 pgs. |
| “U.S. Appl. No. 13,782,421, Response filed Apr. 15, 2015 to Final Office Action dated Jan. 15, 2015”, 6 pgs. |
| “U.S. Appl. No. 13/837,005, Final Office Action dated Aug. 23, 2016”, 9 pgs. |
| “U.S. Appl. No. 13/837,005, Non Final Office Action dated Feb. 17, 2016”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Non Final Office Action dated Jun. 9, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Mar. 5, 2015 to Final Office Action dated Dec. 5, 2014”, 11 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed May 17, 2016 to Non Final Office Action dated Feb. 17, 2016”, 13 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Nov. 9, 2015 to Non Final Office Action dated Jun. 9, 2015”, 11 pgs. |
| “U.S. Appl. No. 13/837,480, Final Office Action dated May 23, 2016”, 11 pgs. |
| “U.S. Appl. No. 13/837,480, Non Final Office Action dated Aug. 11, 2015”, 10 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Jan. 11, 2016 to Non Final Office Action dated Aug. 11, 2015”, 14 pgs. |
| “U.S. Appl. No. 13/840,129, Final Office Action dated Jun. 18, 2015”, 9 pgs. |
| “U.S. Appl. No. 13/840,562, Final Office Action dated Jan. 20, 2016”, 14 pgs. |
| “U.S. Appl. No. 13/840,562, Non Final Office Action dated Apr. 24, 2015”, 23 pgs. |
| “U.S. Appl. No. 13/840,562, Response filed Apr. 18, 2016 to Final Office Action dated Jan. 20, 2016”, 18 pgs. |
| “U.S. Appl. No. 13/840,562, Response filed Jul. 29, 2015 to Non Final Office Action dated Apr. 24, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/841,083, Examiner Summary dated Jan. 29, 2016”, 1 pg. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Jan. 29, 2016”, 11 pgs. |
| “U.S. Appl. No. 13/841,083, Non Final Office Action dated Jul. 15, 2015”, 8 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Apr. 10, 2015 to Non Final Office Action dated Dec. 10, 2014”, 17 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Apr. 28, 2016 to Non Final Office Action dated Jan. 29, 2016”, 11 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Aug. 27, 2014 to Restriction Requirement dated Jul. 21, 2014”, 3 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Oct. 13, 2015 to Non Final Office Action dated Jul. 15, 2015”, 10 pgs. |
| “U.S. Appl. No. 13/841,103, Final Office Action dated Aug. 13, 2015”, 13 pgs. |
| “U.S. Appl. No. 13/841,103, Non Final Office Action dated Jun. 7, 2016”, 16 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Jan. 13, 2016 to Final Office Action dated Aug. 13, 2015”, 11 pg. |
| “U.S. Appl. No. 13/841,103, Response filed Apr. 18, 2016 to Restriction Requirement dated Feb. 19, 2016”, 8 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed May 4, 2015 to Non Final Office Action dated Dec. 4, 2014”, 18 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed Aug. 31, 2016 to Non Final Office Action dated Jun. 7, 2016”, 15 pgs. |
| “U.S. Appl. No. 13/841,103, Restriction Requirement dated Feb. 19, 2016”, 7 pgs. |
| “U.S. Appl. No. 13/987,480, Response filed Jul. 25, 2016 to Final Office Action dated May 23, 2016”, 13 pgs. |
| “U.S. Appl. No. 14/050,950, Final Office Action dated Jun. 17, 2016”, 9 pgs. |
| “U.S. Appl. No. 14/050,950, Non Final Office Action dated Nov. 19, 2015”, 13 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Feb. 19, 2016 to Non Final Office Action dated Nov. 19, 2015”, 11 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Jun. 23, 2015 to Restriction Requirement dated Apr. 23, 2015”, 1 pgs. |
| “U.S. Appl. No. 14/050,950, Response filed Aug. 17, 2016 to Final Office Action dated Jun. 17, 2016”, 8 pgs. |
| “U.S. Appl. No. 14/050,950, Restriction Requirement dated Apr. 23, 2015”, 7 pgs. |
| “U.S. Appl. No. 14/271,722, Notice of Allowance dated Jan. 15, 2016”, 13 pgs. |
| “U.S. Appl. No. 14/803,414, Preliminary Amendment filed Sep. 16, 2015”, 7 pgs. |
| “U.S. Appl. No. 14/803,414, Supplemental Preliminary Amendment Filed Feb. 3, 2016”, 8 pgs. |
| “U.S. Appl. No. 14/808,828,Preliminary Amendment filed Jul. 24, 2015”, 12 pgs. |
| “U.S. Appl. No. 14/808,828, Restriction Requirement dated Aug. 2, 2016”, 6 pgs. |
| “U.S. Appl. No. 14/808,828, Supplemental Preliminary Amendment filed Jul. 27, 2015”, 10 pgs. |
| “U.S. Appl. No. 14/808,828, Supplemental Preliminary Amendment filed Oct. 6, 2015”, 7 pgs. |
| “U.S. Appl. No. 14/830,977, Non Final Office Action dated Apr. 13, 2016”, 16 pgs. |
| “U.S. Appl. No. 14/830,977, Response filed Jul. 13, 2016 to Non Final Office Action dated Apr. 13, 2016”, 10 pgs. |
| “U.S. Appl. No. 14/973,913, Preliminary Amendment filed Mar. 2, 2016”, 10 pgs. |
| “Australian Application Serial No. 2011296356, Response filed Jun. 11, 2015 to First Examiner Report dated Jun. 20, 2014”, 20 pgs. |
| “BioCUE™ Platelet Concentration System”, (Jun. 2010), 2 pgs. |
| “Canadian Application Serial No. 2,772,067, Office Action dated Jan. 8, 2015”, 3 pgs. |
| “Canadian Application Serial No. 2,772,067, Office Action dated Nov. 24, 2015”, 3 pgs. |
| “Canadian Application Serial No. 2,772,067, Response filed Mar. 1, 2016 to Office Action dated Nov. 24, 2015”, 7 pgs. |
| “Canadian Application Serial No. 2,772,067, Response filed Jul. 8, 2015 to Office Action dated Jan. 8, 2015”, 24 pgs. |
| “Canadian Application Serial No. 2,772,069, Office Action dated Sep. 16, 2015”, 3 pgs. |
| “Canadian Application Serial No. 2,772,084, Office Action dated Jun. 11, 2015”, 3 pgs. |
| “Canadian Application Serial No. 2,810,202, Office Action dated Jul. 2, 2015”, 5 pgs. |
| “Canadian Application Serial No. 2,810,202, Response filed Dec. 30, 2015 to Office Action dated Jul. 2, 2015”, 19 pgs. |
| “Canadian Application Serial No. 2,905,552, Voluntary Amendment filed Sep. 11, 2015”. |
| “Canadian Application Serial No. 2,906,310, Voluntary Amendment filed Sep. 14, 2015”, 2 pgs. |
| “Caps for Corning® and Costar® Plastic Labware”, Technical Bulletin, (Dec. 2008), 2 pgs. |
| “Cell Isolation Techniques, Methods and Materials, Working with Enzymes”, Worthington Biochemical Corp, (2004), 9 pgs. |
| “Cell Isolation Theory, Tissue Types”, Worthington Biochemical Corp, (2004), 5 pgs. |
| “Centrifuge Tubes”, Corning Costar, (1996/1997), 76-77. |
| “Chinese Application Serial No. 201080019707.7, Office Action dated Jun. 30, 2014”, in English, 7 pgs. |
| “Chinese Application Serial No. 2010800447744, Notification of Reexamination dated Feb. 23, 2016”, W/ English Translation, 9 pgs. |
| “Chinese Application Serial No. 2010800447744, Response filed Feb. 19, 2015 to Decision on rejection dated Nov. 15, 2014”, (W/ English Translation), 13 pgs. |
| “Chinese Application Serial No. 2010800447744, Response filed Apr. 11, 2016 to Notification of Reexamination dated Feb. 23, 2016”, with English translation of claims, 23 pgs. |
| “Chinese Application Serial No. 2011800457327, Office Action dated Sep. 28, 2015”, No English translation, 6 pgs. |
| “Chinese Application Serial No. 201280030026.X, Office Action dated Nov. 21, 2014”, w/ English Translation, 27 pgs. |
| “Chinese Application Serial No. 201480027541.1, Voluntary Amendment dated May 5, 2016”, w/ English Translation, 15 pgs. |
| “Clotalyst® Autologous Clotting Factor”, “Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Biomet Biologics, (Jan. 2007), 16 pgs. |
| “Corning® 15 and 50 ml Centrifuge Tubes”, Life Sciences. Corning Incorporated., (Jun. 2005), 2 pgs. |
| “Cytori Celution Cell Concentrate Device”, Exhibit 14, 501(k) Summary, FDA approval K060482, (Sep. 28, 2006), 7 pgs. |
| “European Application Serial No. 10712677.3, Examination Notification Art. 94(3) dated Jun. 5, 2013”, 5 pgs. |
| “European Application Serial No. 10754379.5, Response filed Apr. 13, 2015 to Examination Notification Art. 94(3) dated Dec. 15, 2014”, 8 pgs. |
| “European Application Serial No. 10754613.7, Communication Pursuant to Article 94(3) EPC dated Nov. 13, 2015”, 4 pgs. |
| “European Application Serial No. 10754613.7, Response filed Mar. 15, 2016 to Communication Pursuant to Article 94(3) EPC dated Nov. 13, 2015”, 26 pgs. |
| “European Application Serial No. 13165543.3, Response filed Oct. 24, 2014 to Non Final Office Action dated Jun. 27, 2014”, 6 pgs. |
| “European Application Serial No. 14707069.2, Response filed May 23, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Nov. 12, 2015”, 12 pgs. |
| “European Application Serial No. 14707909.9, Communication Pursuant to Article 94(3) EPC dated Jul. 22, 2016”, 9 pgs. |
| “European Application Serial No. 14707909.9, Preliminary Amendment filed on May 13, 2016”, 14 pgs. |
| “European Application Serial No. 14707909.9, Response filed May 13, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Nov. 3, 2015”, 14 pgs. |
| “European Application Serial No. 14709014.6, Office Action dated Nov. 19, 2015”, 2 pgs. |
| “European Application Serial No. 14709803.2, Response filed May 16, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Nov. 5, 2015”, 14 pgs. |
| “European Application Serial No. 14714491.9, Response filed Aug. 1, 2016 to Communication Pursuant to Rules 161 and 162 EPC dated Jan. 21, 2016”, 11 pgs. |
| “European Application Serial No. 14724817.3, Office Action dated Oct. 27, 2015”, 2 pgs. |
| “European Application Serial No. 14724817.3, Response filed May 6, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Oct. 27, 2015”, 13 pgs. |
| “European Application Serial No. 14729994.5, Response filed May 9, 2016 to Communication pursuant to Rules 161(1) and 162 EPC dated Oct. 30, 2015”, 14 pgs. |
| “European Application Serial No. 15184504.7, Extended European Search Report dated Oct. 20, 2015”, 7 pgs. |
| “Fibrostik™ Plasma Concentrator”, Attention Operating Surgeon, Cell Factor Technologies, Inc., (Jul. 2003), 2 pgs. |
| “Frequently Asked Questions, 1. Kits, 2. Enzymes”, Worthington Biochemical Corp, (2003), 3 pgs. |
| “GPS® III Platelet Separation System, Leadership through Technology”, Biomet Biologics, Inc, (Jul. 2007), 8 pgs. |
| “Hemocor HPH® Hemoconcentrator”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/products/hph/index.html>, (Jul. 15, 2004), 2 pgs. |
| “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors”, Symphony II Platelet Concentrate System/PCS brochure, (Jan. 2003), 8 pgs. |
| “International Application Serial No. PCT/US2003/016506, International Search Report dated Oct. 13, 2003”, 2 pgs. |
| “International Application Serial No. PCT/US2007/012587, International Search Report dated Nov. 6, 2007”, 2 pgs. |
| “International Application Serial No. PCT/US2008/004687, International Preliminary Report on Patentability dated Aug. 13, 2009”, 19 pgs. |
| “International Application Serial No. PCT/US2008/004687, International Search Report dated Jul. 2, 2008”, 3 pgs. |
| “International Application Serial No. PCT/US2008/004687, Written Opinion dated Mar. 17, 2009”, 5 pgs. |
| “International Application Serial No. PCT/US2008/004687, Written Opinion dated Jul. 2, 2008”, 5 pgs. |
| “International Application Serial No. PCT/US2009/035564, International Preliminary Examination Report dated Aug. 31, 2010”, 6 pgs. |
| “International Application Serial No. PCT/US2009/035564, International Search Report dated Jul. 3, 2009”, 3 pgs. |
| “International Application Serial No. PCT/US2009/035564, Written Opinion dated Jul. 3, 2009”, 5 pgs. |
| “International Application Serial No. PCT/US2010/029957, International Preliminary Report on Patentability dated Oct. 13, 2011”, 10 pgs. |
| “International Application Serial No. PCT/US2010/029957, International Search Report dated Jul. 30, 2010”, 6 pgs. |
| “International Application Serial No. PCT/US2010/029957, Written Opinion dated Jul. 30, 2010”, 9 pgs. |
| “International Application Serial No. PCT/US2010/041942, International Preliminary Report on Patentability dated Jan. 26, 2012”, 9 pgs. |
| “International Application Serial No. PCT/US2010/041942, International Search Report dated Oct. 8, 2010”, 3 pgs. |
| “International Application Serial No. PCT/US2010/041942, Written Opinion dated Oct. 8, 2010”, 8 pgs. |
| “international Application Serial No. PCT/US2011/031954, Written Opinion dated Aug. 9, 2011”, 9 pgs. |
| “International Application Serial No. PCT/US2011/045290, International Search Report dated Nov. 7, 2011”, 5 pgs. |
| “International Application Serial No. PCT/US2011/045290, Written Opinion dated Nov. 7, 2011”, 5 pgs. |
| “International Application Serial No. PCT/US2012/034104, International Preliminary Report on Patentability dated Oct. 31, 2013”, 7 pgs. |
| “International Application Serial No. PCT/US2012/034104, International Search Report dated Oct. 29, 2012”, 5 pgs. |
| “International Application Serial No. PCT/US2012/034104, Written Opinion dated Oct. 29, 2012”, 6 pgs. |
| “International Application Serial No. PCT/US2013/056793, International Preliminary Report on Patentability dated Mar. 12, 2015”, 8 pgs. |
| “International Application Serial No. PCT/US2013/056793, International Search Report dated Dec. 5, 2013”, 3 pgs. |
| “International Application Serial No. PCT/US2013/056793, Written Opinion dated Dec. 5, 2013”, 6 pgs. |
| “International Application Serial No. PCT/US2014/016384, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016421, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016895, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/016900, International Preliminary Report on Patentability dated Sep. 24, 2015”, 9 pgs. |
| “International Application Serial No. PCT/US2014/021707, International Preliminary Report on Patentability dated Sep. 24, 2015”, 16 pgs. |
| “International Application Serial No. PCT/US2014/023091, International Preliminary Report on Patentability dated Sep. 24, 2015”, 11 pgs. |
| “International Application Serial No. PCT/US2014/028942, International Preliminary Report on Patentability dated Sep. 24, 2015”, 15 pgs. |
| “Japanese Application Serial No. 2010-503066, Office Action dated Jan. 22, 2013”, w/ English Translation, 17 pgs. |
| “Japanese Application Serial No. 2012-503768, Office Action dated May 20, 2014”, w/ English Translation, 5 pgs. |
| “Japanese Application Serial No. 2012-520742, Office Action dated Sep. 9, 2014”, w/ English Translation, 6 pgs. |
| “Japanese Application Serial No. 2012-526990, Examiners Decision of Final Refusal dated Jun. 3, 2016”, W/ English Translation, 6 pgs. |
| “Japanese Application Serial No. 2012-526990, Office Action dated Jun. 26, 2015”, (W/ English Translation), 12 pgs. |
| “Japanese Application Serial No. 2012-526990, Response filed Dec. 25, 2015 to Office Action dated Jun. 26, 2015”, (W/ English Translation), 14 pgs. |
| “Japanese Application Serial No. 2012-527030, Office Action dated Jun. 12, 2015”, (English translation), 2 pgs. |
| “Japanese Application Serial No. 2013-174962, Notice of Reasons for Rejection dated Jul. 31, 2015”, W/ English Translation, 10 pgs. |
| “Japanese Application Serial No. 2013-174962, Response filed Mar. 12, 2015 to Office Action dated Sep. 12, 2014”, (W/ English Translation), 18 pgs. |
| “Japanese Application Serial No. 2013-174962, Response filed Oct. 30, 2015 to Notice of Reasons for Rejection dated Jul. 31, 2015”, W/ English Claims, 16 pgs. |
| “Japanese Application Serial No. 2013-527119, Office Action dated Mar. 1, 2016”, W/ English Translation, 12 pgs. |
| “Japanese Application Serial No. 2013-527119, Office Action dated Jun. 12, 2015”, (W/ English Translation), 11 pgs. |
| “Japanese Application Serial No. 2013-527119, Response filed Aug. 1, 2016 to Office Action dated Mar. 1, 2016”, 13 pgs. |
| “Japanese Application Serial No. 2013-527119, Response filed Oct. 1, 2015 to Office Action dated Jun. 12, 2015”, 12 pgs. |
| “Japanese Application Serial No. 2014-024420, Preliminary Notice of Reasons for Rejection dated Feb. 24, 2015”, w/ English Translation, 15 pgs. |
| “Knee Cartilage Implantation Carticel™, Autologous Cultured Chondrocyte Implantation”, The Sports Medicine Center, [Online]. Retrieved from the Internet: <http://www.orthoassociates.com/carticel.htm>, (Apr. 6, 2006), 7 pgs. |
| “Letter CryoSeal FS System. Vaccines, Blood & Biologics”, FDA U.S. Food and Drug Administation., http://www.fda.gov/BiologicsBioodVaccines/BioodBioodProducts/ApprovedProducts/Premarket ApprovalsPMAs/ucm091631.htm, (Jul. 26, 2007), 21 pgs. |
| “MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study”, Retriewed From Intenet : <http://www.biomet.com/patients/clinical recruitment padstudy.cfm>, (Jul. 2, 2009), 2 pgs. |
| “MarrowsTim™ Concentration System”, Biomet Biologics, Inc, (Feb. 15, 2008), 20 pgs. |
| “Medical Applications: Blood Filtration”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/industries/medical/blood_filter.html>, (Jul. 15, 2004), 1 pg. |
| “Minivalve international: duckbill valves—du 054.001 sd”, [Online]. Retrieved from the Internet: <http://www.minivalve.com/htm/DV054.htm>, 1 pg. |
| “Momentive Silopren*LSR 2050”, (Jun. 30, 2014), 3 pg. |
| “Platelet Rich Plasma (PRP)”, The Stone Clinic, (May 2006), 2 pgs. |
| “Prosys PRP Kit”, Tozai Holdings, Inc. EC21 Global B2B Marketplace, Retrieved From Internet : <http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web>, (Jul. 18, 2011), 5 pgs. |
| “Renaflo® II Hemofilter”, Minntech® Filtration Technologies Group, Minntech Corporation (2004), <http://www.minntech.com/ftg/products/renaflo/index.html>, (Jul. 15, 2004), 2 pgs. |
| “Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet”, Sigma-Aldrich, (2003), 1-2. |
| “SmartPrep PRP-20 Procedure Pack—Instructions for Use”, Harvest, 12 pgs. |
| “ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc”, noblood: Transfusion Alternatives Patient Blood Mangement, [Online]. Retrieved from the Internet: <URL: http://noblood.org/forum/threads/2128-ThermoGenesis-Corp-to-Supply-Autologous-Thrombin-Kits-to-Biomet-Inc>, (Apr. 5, 2005), 3 pgs. |
| “Vernay Product Information Sheet, Umbrella Check Valve”, Part No. V251010200. (Jul. 2013), 2 pgs. |
| Andia, Isabel, et al., “Platelet-rich plasma for managing pain and inflammation in osteoarthritis”, Nature Reviews Rheumatology, vol. 9. No. 12., (Oct. 1, 2013), 721-730. |
| Badiavas, Evangelos V., et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells”, Arch Dermatol. 139, (Apr. 2003), 510-516. |
| Bang, N U, et al., “Plasma Protein Requirements for Human Platelet Aggregation”, Acad Sci, 201, (1972), 280-299. |
| Berguer, R, et al., “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports”, J Trauma 31. (1991), 408-411. |
| Berruyer, M, et al., “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors”, J Thorac Cardiovasc Sura 105, (1993), 892-7. |
| Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days”, Vox Sanq, vol. 68, (Feb. 1995), 82-89. |
| Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Grafts Heal Canine Seqmental Defects, Journal of Orthopaedic Research, (May 2006), 857-866. |
| Carpenter, et al., “Rationale Design of stable protein formulations-theory and practice”, Rationale design of stable lyophilized protein formulations: theory and practice,, (2002), 109-133. |
| Casali, B, et al., “Fibrin glue from single-donation autologous plasmapheresis”, Transfusion 32, (1992), 641-643. |
| Clayden, J D, et al., “Improved segmentation reproducibility in group tractography using a quantitative tract similarity measure”, Neuroimage, Academic Press, Orlando, FL, US vol. 33, No. 2, (Nov. 1, 2006), 482-492. |
| Collier, B S, et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda Blood, vol. 47, No. 5, (May 1976). |
| Connolly, John, et al., “Development of an Osteogenic Bone-Marrow Preparation”, The Journal of Bone and Joint SurQery, Incorporated. vol. 71-A, No. 5, (Jun. 1989), 684-691. |
| Connolly, John F., “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair”, Clinical Orthopaedics and Related Research 313, (Apr. 1995), 8-18. |
| Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination”, Healing of Bone Defects, Journal of Orthopaedic Research, (May 2006), 877-888. |
| Dayer, Jean-Michel, et al., “Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra)”, Annals of the New York Academy of Sciences. vol. 1069, (Jun. 2006), 444-53. |
| De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow”, Cells Tissues Organs 174, (2003), 101-109. |
| De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow”, Immunology Letters 89, (2003), 267-270. |
| De Wit, et al., “Experiments on the Preparation of Blood Components with the IBM 2991 Blood Cell Processor”, Vox Sang. 29, (Feb. 10, 1975), 352-362. |
| Delrossi, A, et al., “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass”, J Thorac Cardiovasc Sura 100, (Aug. 1990), 281-285. |
| Depalma, L, “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods”, Transfusion vol. 33, No. 9, (1993), 717-720. |
| Deugarte, M D, et al., “Future of Fat as Raw Material for Tissue Regeneration”, Lippincott Williams & Wilkins, Inc., (2007), 215-219. |
| Dimuzio, Paul, et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells”, Vasucular, vol. 14, No. 6, (2006), 338-342. |
| Edlich, Richard F, et al., “Surgical Devices in Wound Healing Management”, In Wound Healing: Biochemical & Clinical Aspects 1st ed., vol. Philadelphia: W.B. Saunders Company, (1992), 581-601. |
| Ehricke, H H, et al., “Visualizing MR diffusion tensor fields by dynamic fiber tracking and uncertainty mapping”, Computers and Graphics, Elsevvier vol. 30, No. 2, (Apr. 1, 2006), 255-264. |
| Epstein, G H, et al., “A new autologous fibrinogen-based adhesive for otologic surgery”, Ann Otol Rhinol Laryngol 95, (May 25-26, 1985), 40-45. |
| Fini, et al., “Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies”, Biomedicine and Pharmacotherapy, Elsevier, FR, vol. 59, No. 7, (Aug. 1, 2005), 388-394. |
| Fraser, John K, et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes”, Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1, (Mar. 2006), S33-S37. |
| Friesen, Robert, et al., “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass”, Anesth, Analg, (1993), 702-707. |
| Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches”, Pathol Bioi (Paris), 53—Abstract only, (Dec. 2005), 2 pgs. |
| Gerald, Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”, Biopolymers, vol. 27, (1988), 763-774. |
| Gibble, et al., “Fibrin glue: the perfect operative sealant”, Transfusion, 1990, vol. 30, No. 8., (1990), 741-747. |
| Gimble, Jeffrey M, “Adipose-Derived Stem Cells for Regenerative Medicine”, Circulation Research American Heart Association, Inc., (May 11, 2007), 1249-1260. |
| Gomillion, Cheryl T, et al., “Stem cells and adipose tissue engineering”, Biomaterials 27, Science Direct Elsevier, (2006), 6052-6063. |
| Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells”, Stem Cells: Concise Review, (Jan. 2004), 487-500. |
| Guilak, Farshid, et al., “Adipose-derived adult stem cells for cartilage tissue engineering”, Biorheology 41, (2004), 389-399. |
| Harris, E. L.V, et al., “Protein Purification Methods—A Practical Approach”, Clarification and Extraction, (1989), 7 pgs. |
| Hartman, A. R, et al., “Autologous whole plasma fibrin gel. Intraoperative procurement”, Arch Surg 127, (Mar. 1992), 357-359. |
| Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source”, Cells Tissues Organs, (2004), 2-12. |
| Haynesworth, S E, et al., “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate”, 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462, (2002), 1 pg. |
| Hennis, H L, et al., “Infectious disease risks of fibrin glue [letter]”, Ophthalmic Sura 23, (Sep. 1992), 1 pg. |
| Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells”, Journal of Bone & Joint Surgery, (Jul. 2005), 1430-1437. |
| Hiromasa, Mitsuhata, et al., “An Anaphylactic Reaction to Topical Fibrin Glue”, Anesthesiology, vol. 81, No. 4, (Oct. 1994), 1074-1077. |
| Hom, D, et al., “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound”, The Laryngoscope, vol. 113, (Sep. 2003), 1566-1571. |
| Hood, Andrew G, et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties”, (Jan. 1993), 126-129. |
| Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration”, 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, (2006), 1 pg. |
| Jackson, C M, et al., “Blood coagulation”, Annu Rev Biochem 49: 765-811, (1980), 22 pgs. |
| Jayadev, Suprya, “Trypsinization of Adherent Cells”, (Aug. 8, 1991), 1 pg. |
| Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:, (Oct. 1999), S156-S162. |
| Jones, D K, et al., “Confidence mapping in diffusion ensor magnetic resonance imaging tractography using a bootstrap approach”, Magnetic Resonance in Medicine Wiley USA, vol. 53 , No. 5, (May 2005), 1143-1149. |
| Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis”, Annals of Rheumatic Diseases, (Aug. 2000), 5 pgs. |
| Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2, (Feb. 1978), 307-316. |
| Kim, Sun Jin, et al., “Development of a novel sustained release formulation of recombinant human growth homrone using sodium hyaluronate microparticles”, Journal of Controlled Release, 2005, vol. 104,, (2005), 323-335. |
| Kjaergard, H. K, et al., “A simple method of preparation of autologous fibrin glue by means of ethanol”, Surg Gynecol Obstet 175, (1992), 72-3. |
| Kjaergard, H. K, “Preparation of autologous fibrin glue from pericardial Blood”, Ann Thorac Sur 55, (1993), 543-4. |
| Kohsaka, Hitoshi, “Gene Transfer Therapy for Rheumatoid Arthritis”, Japanese Journal of Clinical Medicine, No. 63, No. 9, (2005), 8 pgs. |
| Kuderma, H. et al., “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven”, Wein Klin Wochenschr 87—Not in English, (Aug. 15, 1975), 6 pgs. |
| Kumar, Vijay, et al., “Autologous Thrombin: Intraoperative Production From Whole Blood”, Journal of American Society of Extra-Corporeal Technology. JECT, 40, (2008), 94-98. |
| Kumar, Vijay, et al., “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device”, Journal of American Society of Extra-Corporeal Technology JECT, 37, (Mar. 2005), 390-395. |
| Kumar, Vijay, et al., “Whole Blood Thrombin: Development of a Process for lntra-Operative Production of Human Thrombin”, Journal of American Society of Extra-Corporeal Technology JECT, 39, (Apr. 2007), 18-23. |
| Kwon, Young-Bae, et al., “Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat”, Journal of Vetrinary Science 7(2), (2006), 105-109 pgs. |
| Kyosti Laitakari, M D, et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”, Laryngoscope vol. 99, (Sep. 1989), 974-976. |
| Laplante, Ben L, et al., “Spine osteoarthritis”, PM&R, vol. 4, (2012), S28-S36. |
| Lasher, Lisa, “My Experience with PRP”, PowerPoint presentation, <http://www.cellfactortech.com/global_products.cfm>, (Sep. 16, 2005), 35 pgs. |
| Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report”, Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery, (2004), 370-373. |
| Lerner, R, et al., “Current status of surgical adhesives”, J Surg Res 48, (Feb. 1990), 165-80. |
| Longas, Maria O, “An Improved Method for the Purification of Human Fibrinogen”, J. Biochem vol. 11, (1980), 559-564. |
| Lori, N F, et al., “Diffusion tensor fiber tracking of human brain connectivity: acquisition methods, reliability analysis and biological results”, NMR in Biomedicine Wiley UK, vol. 15, No. 7-8, (Nov. 2002), 493-515. |
| Lu, X, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair”, 19(1) Abstract, (Jan. 2002), 2 pgs. |
| Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix”, Journal of Biomedical Materials Research Part B: Applied Biomaterials, (Apr. 2007), 49-57. |
| Masri, Marwan A, et al., “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000”, Thromb Haemostas (Struttgart) vol. 49 (2), (1983), 116-119. |
| Matras, Helene, “Fibrin Seal: The State of the Art”, Journal of Oral Maxillofacial Surgery, vol. 43, (1985), 605-611. |
| Matuska, et al., “Autologous Solution Protects Bovine Cartilage Explants from IL-1a and STFa-Induced Cartilage Degradation”, Journal of Orthopaedic Research, (Jul. 16, 2013), 7 pgs. |
| Mehmet, C, et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”, Ann Thorac Surg, vol. 53, (1992), 530-531. |
| Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005), 2 pgs. |
| Moretz, W., et al., “A simple autologous fibrinogen glue for otologic surgery”, Otolarvnaol Head Neck Surg 95, (Jul. 1986), 122-4. |
| Nakagami, Hironori, et al., “Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells”, Angiogenesis by Adipose Tissue-Derived Cells, American Heart Association, Inc., (Dec. 2005), 2542-2547. |
| Nathan, Suresh, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue”, Tissue Engineering, vol. 9, No. 4, Mary Ann Liebert, Inc., (2003), 733-744. |
| Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs”, The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, (Aug. 1986), 635-642. |
| Okamoto, Y, et al., “Determination of soluble tumor necrosis factor-alpha receptor type (TNFRI) and II (TNFRII) in the urine of healthy Japanese subjects”, Journal of Immunoassay and Immunochemistry, 2011, vol. 32, (2011), 145-155. |
| Orphardt, Charles E, “Denaturation of Proteins”, Virtual Chembook, Elmhurst College, <http://www.elmhurst.edu/chm/vchembook/568denaturation.html> (web accessed Mar. 9, 2011), (2003), 3 pgs. |
| Parchment, et al., “Roles for in vitro myelotoxicity tests in preclincial drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologist”, vol. 21, No. 2, (1993), 241-250. |
| Parker, Anna M, et al., “Adipose-derived stem cell for the regeneration of damaged tissues”, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Bioi. Ther., Informa UK Ltd, (2006), 567-578. |
| Planat-Benard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells”, Adipose-Derived Cell Cardiomyocyte, American Heart Association, Inc., (Feb. 6, 2004), 223-229. |
| Ponticiello, Michael S, “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc., (2006), 1 pg. |
| Rangappa, Sunil, et al., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes”, Adult Stem Cells Transformed into Cardiomyoctyes, Ann Thorac Surg, (2003), 775-779. |
| Rigotti, M D, et al., “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells”, Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007), 1409-1422. |
| Robert, Quigley L, et al., “Intraoperative Procurement of Autologous Fibrin Glue”, Ann Thorac Surg, vol. 56, (1993), 387-389. |
| Rubin, M. D., et al., “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells”, Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007), 1423-1424. |
| Sadeghi, M, et al., “Strikingly higher interleukin (IL)-1a, IL-1b and soluble interleukin-1 receptor antagonist (slL-1RA) but similar IL-2, sll-2R, IL-3, IL-4, IL-6, sll-6R, IL-10, tumour necrosis factor (TNF)-a, transforming growth factor (TGF)-B2, (cont.)”, (Title cont. “transforming growth factor (TGF)-(32 and interferon IFN-y urine Levels in healthy females compared to healthy males: protection against urinary tract injury?”) Clinical and Experimental Immunology, vol. 142, (2005), 312-317. |
| Sanal, M, et al., “Does fibrin glue cause foreign body reactions?”, Eu r J Pediatr Sura 2, (1992), 285-6. |
| Schaffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies”, Tissue-Specific Stem Cells, Stem Cells®, (Apr. 10, 2007), 12 pgs. |
| Schmidt, K G, “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, (1979), 97-106. |
| Schmidt, K G, et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23, (1979), 88-96. |
| Semple, Elisabeth, et al., “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, a New Thrombin-Processing Device”, Journal of American Society Extra-Corporeal Technology, 37(2), (2005), 196-200. |
| Sevenoaks, Martin J., et al, “Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity—a common inflammatory phenotype?”, respiratory Research vol. 7:70, (2006), 1-9. |
| Shiozawa, Kazuko, et al., “Gene Therapy, Is a total therapy for rheumatoid arthritis possible?”, Pharma Medica, vol. 17, No. 10 w/ partial English Translation, (1999), 16 pgs. |
| Shu-Li, Lin, et al., “Static magnetic field attenuates mortality rate of mice by increasing the production of IL-1 receptor antagonist”, Int. J. Radiat. Biol. 2009, 85(7), (Jul. 31, 2009), 633-640. |
| Siedentop, Karl H, et al., “Autologous Fibrin Tissue Adhesive”, Laryngoscope, vol. 95, (Sep. 1985), 1074-1076. |
| Siedentop, Karl H, et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”, Laryngoscope, vol. 96, (Oct. 1986), 1062-1064. |
| Sierra, D H, “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications”, J Biomater Appl 7, (Apr. 1993), 309-52. |
| Silver, Frederick H, et al., “Review Preparation and use of fibrin glue in surgery”, Biomaterials 16 (1995), (1995), 891-903. |
| Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery”, Scand J Thor Cardiovasc Surg 22, (1988), 271-274. |
| Spotnitz, William D, et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”, The American Surgeon, vol. 55,, (Mar. 1989), 166-168. |
| Sutton, Robin G, et al., “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass”, Ann Thorac Surg (1993) vol. 56, (1993), 6 pgs. |
| Takahashi, Kazutoshi, et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors”, Cell, Elsevier Inc., (Nov. 30, 2007), 1-12. |
| Tawes, Jr., Roy L, et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”, The American Journal of Surgery, vol. 168, (Aug. 1994), 120-122. |
| Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”, Drug Intelligence and Clinical Pharmacy, vol. 22, (Dec. 1988), 946-952. |
| Toriumi, Dean M, et al., “Surgical Tissue Adhesives in Otolaryngology-Head and Neck Surgery”, Otolaryngologic Clinics of North America, vol. 27, No. 1, (Feb. 1994), 203-209. |
| Weis-Fogh, U S, “Fibrinogen prepared from small blood samples for autologous use a tissue adhesive system”, Eur Surg Res 20, (1988), 381-9. |
| Weisman, M D, “Biochemical Characterization of Autologous Fibrinogen Adhesive”, Laryngoscope 97, (Oct. 1987), 1186-1190. |
| Wiseman, David M, et al., “Wound Dressings: Design and Use”, In Wound Healing: Biochemical & Clinical Aspects 1st ed., vol., (1992), 562-580. |
| Yoon, Eulsik, et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model”, Tissue Engineering, vol. 13, No. 3, (2007), 619-627. |
| Zhang, Duan-Zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction”, Chinese Medical Journal, vol. 120, No. 4 General Hospital of Shenyang Military Region, (2007), 300-307. |
| Zuk, P. A, et al., “Multilineage cells from human adipose tissue: Implications for cellbased therapies”, Tissue Engineering, 7(2), XP00219871 0, ISSN: 1076-3279, (Apr. 1, 2001), 211-228. |
| “U.S. Appl. No. 12/394,723, Non Final Office Action dated Oct. 5, 2016”, 16 pgs. |
| “U.S. Appl. No. 12/549,116, Non Final Office Action dated Oct. 6, 2016”, 15 pgs. |
| “U.S. Appl. No. 13/392,266, Non Final Office Action dated Oct. 4, 2016”, 21 pgs. |
| “U.S. Appl. No. 13/837,005, Advisory Action dated Dec. 2, 2016”, 3 pgs. |
| “U.S. Appl. No. 13/837,005, Response filed Oct. 24, 2016 Final Office Action dated Aug. 23, 2016”, 9 pgs. |
| “U.S. Appl. No. 13/837,480, Non Final Office Action dated Sep. 13, 2016”, 9 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Jul. 25, 2016 to Final Office Action dated May 23, 2016”, 13 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Dec. 12, 2016 to Non Final Office Action dated Sep. 13, 2016”, 13 pgs. |
| “U.S. Appl. No. 13/841,083, Final Office Action dated Sep. 9, 2016”, 10 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed Nov. 29, 2016 to Final Office Action dated Sep. 9, 2016”, 12 pgs. |
| “U.S. Appl. No. 13/841,103, Final Office Action dated Dec. 14, 2016”, 24 pgs. |
| “U.S. Appl. No. 14/050,950, Notice of Allowance dated Oct. 6, 2016”, 12 pgs. |
| “U.S. Appl. No. 14/803,414, Restriction Requirement dated Oct. 20, 2016”, 7 pgs. |
| “U.S. Appl. No. 14/808,828, Non Final Office Action dated Dec. 8, 2016”, 10 pgs. |
| “U.S. Appl. No. 14/808,828, Response filed Oct. 3, 2016 to Restriction Requirement dated Aug. 2, 2016”, 7 pgs. |
| “U.S. Appl. No. 14/830,977, Final Office Action dated Oct. 20, 2016”, 12 pgs. |
| “U.S. Appl. No. 14/841,086, Examiners Interview Summary dated Nov. 7, 2016”, 3 pgs. |
| “Arthritis”, Mayo Clinic, (Jan. 22, 2013), 1-5. |
| “Canadian Application Serial No. 2,772,069, Office Action dated Jul. 20, 2016”, 5 pgs. |
| “Chinese Application Serial No. 201480027408.6, Voluntary Amendment dated Jun. 8, 2016”, W/ English Claims, 50 pgs. |
| “European Application Serial No. 10749582.2, Communication Pursuant to Article 94(3) EPC dated May 10, 2016”, 4 pgs. |
| “European Application Serial No. 10749582.2, Response filed Aug. 26, 2016 to Communication Pursuant to Article 94(3) EPC dated May 10, 2016”, 13 pgs. |
| “European Application Serial No. 14707069.2, Communication Pursuant to Article 94(3) EPC dated Nov. 15, 2016”, 7 pgs. |
| “European Application Serial No. 14707909.9, Response filed Dec. 6, 2016 to Communication Pursuant to Article 94(3) EPC dated Jul. 22, 2016”, 11 pgs. |
| “European Application Serial No. 14709014.6, Communication Pursuant to Article 94(3) EPC dated Oct. 20, 2016”, 12 pgs. |
| “European Application Serial No. 14709014.6, Response filed May 27, 2016 to Office Action dated Nov. 19, 2015”, 15 pgs. |
| “European Application Serial No. 15184504.7, Communication Pursuant to Article 94(3) EPC dated Sep. 16, 2016”, 5 pgs. |
| “Japanese Application Serial No. 2013-527119, Examiners Decision of Final Refusal dated Oct. 18, 2016”, W/ English Translation, 9 pgs. |
| Belal, Mahmoud Helmy, “Recombinant Human Platelet-Derived Growth Factor-BB: a promising role for fibroblast cell attachment in chronic periodontitis. A concentration-dependent effect on human cell adhesion: SEM study”, Rev. Clín. Pesq. Odontol., Curitiba, v. 5, n. 3, (2009), p. 225-240. |
| Honore, Prisca, et al., “Interleukin-1aB gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain”, Behavioral Brain Research, (2006), 355-364. |
| Nalamachu, Srinivas, “An Overview of Pain Management: The Clinical Efficacy and Value of Treatment”, Am. J. Manag. Care. 19, (2013), 261-266. |
| Re, Fabio, et al., “Expression of interleukin-1 receptor antagonist (IL-ra) by human circulating polymorphonuclear cells”, European Journal of Immunology, 23, (1993), 570-573 pgs. |
| Sarzi-Puttini, Piercarlo, et al., “The Appropriate Treatment of Chronic Pain”, Clin. Drug Investig. 32, (2012), 21-33. |
| Shrivastava, Abha, et al., “Effects of Electromagnetic Forces of Earth on Human Biological System”, Indian J. Prev. Soc. Med, Retrieved from the Internet: <URL:http://medind.nic.in/ibl/t09/i3/iblt09i3p162.pdf>, (Jan. 1, 2009), 162-167. |
| Tiaka, Elisavet K., et al., “Epidermal Growth Factor in the Treatment of Diabetic Foot Ulcers: An Update”, Perspectives in Vascular Surgery and Endovascular Therapy 24(1), (2012), p. 37-44. |
| Younger, Jarred, et al., “Pain Outcomes: A Brief Review of Instruments and Techniques”, Curr Pain Headache Rep. 13(1), (Feb. 2009), p. 39-43. |
| “U.S. Appl. No. 12/394,723, Final Office Action dated May 15, 2017”, 14 pgs. |
| “U.S. Appl. No. 13/837,005, Notice of Allowance dated May 18, 2017”, 10 pgs. |
| “U.S. Appl. No. 13/837,480, Final Office Action dated May 4, 2017”, 12 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Aug. 7, 2017 to Final Office Action dated May 4, 2017”, 12 pgs. |
| “U.S. Appl. No. 13/841,083, Notice of Allowance dated Sep. 7, 2017”, 8 pgs. |
| “U.S. Appl. No. 13/841,083, Response filed May 24, 2017 to Non Final Office Action dated Feb. 24, 2017”, 18 pgs. |
| “U.S. Appl. No. 13/841,083, Supplemental Amendment filed Aug. 29, 2017 to Non Final Office Action dated Feb. 24, 2017”, 9 pgs. |
| “U.S. Appl. No. 13/841,103, Examiner Interview Summary dated Jun. 8, 2017”, 1 pg. |
| “U.S. Appl. No. 13/841,103, Non Final Office Action dated Jun. 8, 2017”, 13 pgs. |
| “U.S. Appl. No. 13/841,103, Response filed Sep. 8, 2017 to Non Final Office Action dated Jun. 8, 2017”, 12 pgs. |
| “U.S. Appl. No. 14/803,414, Response filed Jul. 10, 2017 to Non Final Office Action dated Apr. 19, 2017”, 15 pgs. |
| “U.S. Appl. No. 14/808,828, Amendment Under 37 C.F.R. § 1.312 Filed”, 6 pgs. |
| “U.S. Appl. No. 14/808,828, Notice of Allowance dated May 19, 2017”, 9 pgs. |
| “U.S. Appl. No. 14/808,828, PTO Response to Rule 312 Communication dated Jun. 8, 2017”, 2 pgs. |
| “U.S. Appl. No. 14/830,977, Non Final Office Action dated Aug. 7, 2017”, 12 pgs. |
| “U.S. Appl. No. 15/616,548, Preliminary Amendment filed Jun. 7, 2017”, 6 pgs. |
| “U.S. Appl. No. 15/616,548, Supplemental Preliminary Amendment Filed Aug. 17, 2017”, 6 pgs. |
| “Chinese Application Serial No. 201480027655.6, Office Action dated May 15, 2017”, (W/ English Translation), 11 pgs. |
| “European Application No. 14707909.9, Summons to Attend Oral Proceedings dated Aug. 10, 2017”, 7 pgs. |
| “European Application Serial No. 10754613.7, Response filed Aug. 16, 2017 to Non Final Office Action dated Feb. 7, 2017”, 20 pgs. |
| “European Application Serial No. 14707909.9, Response filed Apr. 26, 2017 to Communication Pursuant to Article 94(3) EPC dated Dec. 16, 2016”, 25 pgs. |
| “European Application Serial No. 14709014.6, Summons to Attend Oral Proceedings dated Jun. 7, 2017”, 8 pgs. |
| “European Application Serial No. 14724817.3, Office Action dated Jun. 29, 2017”, 5 pgs. |
| “European Application Serial No. 15184504.7, Communication Pursuant to Article 94(3) EPC dated Jul. 28, 2017”, 13 pgs. |
| “European Application Serial No. 15184504.7, Response filed Jun. 12, 2017 to Communication Pursuant to Article 94(3) EPC dated Feb. 13, 2017”, 10 pgs. |
| Pettit, et al., “The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals”, Trends in Biotechnology, (1998), 343-349. |
| “U.S. Appl. No. 12/394,723, Final Office Action dated May 18, 2018”, 9 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Jun. 18, 2018 to Final Office Action dated May 18, 2018”, 7 pgs. |
| “U.S. Appl. No. 14/830,977, Response filed May 23, 2018 to Final Office Action dated Feb. 23, 2018”, 11 pgs. |
| “U.S. Appl. No. 14/973,913, Response filed Apr. 16, 2018 to Non Final Office Action dated Jan. 16, 2018”, 12 pgs. |
| “U.S. Appl. No. 15/836,249, Non Final Office Action dated Apr. 6, 2018”, 10 pgs. |
| “Australian Application Serial No. 2014237269, Response filed May 21, 2018 to First Examination Report dated Dec. 11, 2017”, 25 pgs. |
| “Australian Application Serial No. 2014237679, Response filed Apr. 23, 2018 to First Examination Report dated Dec. 11, 2017”. |
| “Australian Application Serial No. 2014237679, Subsequent Examiners Report dated May 29, 2018”, 4 pgs. |
| “Australian Application Serial No. 2014238304, Response filed May 15, 2018 to First Examination Report dated Jan. 29, 2018”, 50 pgs. |
| “Australian Application Serial No. 2014238363, Response filed May 14, 2018 to First Examination Report dated Feb. 8, 2018”, 14 pgs. |
| “Australian Application Serial No. 2014238367, Response filed May 15, 2018 to First Examination Report dated Feb. 16, 2018”, 23 pgs. |
| “Chinese Application Serial No. 201480027178.3, Response filed Feb. 26, 2018 to Office Action dated Oct. 10, 2017”, (W/ English Claims), 10 pgs. |
| “Chinese Application Serial No. 201480027541.1, Office Action dated Mar. 14, 2018”, (W/ English Translation), 14 pgs. |
| “Chinese Application Serial No. 201480027655.6, Office Action dated Feb. 23, 2018”, (W/ English translation), 15 pgs. |
| “European Application Serial No. 10754613.7, Response filed Mar. 29, 2018 to Communication Pursuant to Article 94(3) EPC dated Nov. 28, 2017”, 15 pgs. |
| “European Application Serial No. 14724817.3, Communication Pursuant to Article 94(3) EPC dated Apr. 5, 2018”, 4 pgs. |
| “European Application Serial No. 18160602.1, Extended European Search Report dated Apr. 30, 2018”, 9 pgs. |
| Botti, C, et al., “Autologous bone marrow cell therapy for peripheral arterial disease”, Stem Cells and Cloning: Advances and Applications, No. 5, (2012), 5-14. |
| Kubis, N, et al., “Vasculogenesis and Angiogenesis: Molecular and Cellular Controls Part 1: Growth Factors”, vol. 9, No. 3, (2003), 227-237. |
| Milkiewicz, M, et al., “Regulators of angiogenesis and strategies for their therapeutic manipulation”, The International Journal of Biochemistry & Cell Biology, vol. 38, No. 3, (2006), 333-357. |
| Morishita, R, et al., “Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease”, Hypertension, vol. 44, No. 2, (2004), 203-209. |
| Richard, J Powell, et al., “Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: Results of the HGF-0205 trial”, Journal of Vascular Surgery, vol. 52, No. 6, (2010), 1525-1530. |
| “U.S. Appl. No. 12/394,723, Non Final Office Action dated Nov. 14, 2017”, 18 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Feb. 14, 2018 to Non Final Office Action dated Nov. 14, 2017”, 27 pgs. |
| “U.S. Appl. No. 12/394,723, Response filed Oct. 16, 2017 to Final Office Action dated May 15, 2017”, 18 pgs. |
| “U.S. Appl. No. 13/837,480, Non Final Office Action dated Dec. 8, 2017”, 9 pgs. |
| “U.S. Appl. No. 13/837,480, Response filed Mar. 8, 2018 to Non Final Office Action dated Dec. 8, 2017”, 13 pgs. |
| “U.S. Appl. No. 13/841,103, Notice of Allowance dated Oct. 11, 2017”, 8 pgs. |
| “U.S. Appl. No. 13/841,103, Supplemental Preliminary Amendment filed Sep. 26, 2017”, 7 pgs. |
| “U.S. Appl. No. 14/803,414, Final Office Action dated Oct. 18, 2017”, 26 pgs. |
| “U.S. Appl. No. 14/803,414, Response field Dec. 18, 2017 to Final Office Action dated Oct. 18, 2017”, 13 pgs. |
| “U.S. Appl. No. 14/830,977, Final Office Action dated Feb. 23, 2018”, 10 pgs. |
| “U.S. Appl. No. 14/830,977, Response filed Nov. 6, 2017 to Non Final Office Action dated Aug. 7, 2017”, 13 pgs. |
| “U.S. Appl. No. 14/973,913, Non Final Office Action dated Jan. 16, 2018”, 7 pgs. |
| “U.S. Appl. No. 14/973,913, Response filed Dec. 20, 2017 to Restriction Requirement dated Oct. 20, 2017”, 8 pgs. |
| “U.S. Appl. No. 14/973,913, Restriction Requirement dated Oct. 20, 2017”, 7 pgs. |
| “U.S. Appl. No. 15/836,249, Preliminary Amendment filed Mar. 9, 2018”, 9 pgs. |
| “Australian Application Serial No. 2014229070, First Examination Report dated Nov. 24, 2017”, 3 pgs. |
| “Australian Application Serial No. 2014229070, Response filed Jan. 15, 2018 to First Examination Report dated Nov. 24, 2017”, 25 pgs. |
| “Australian Application Serial No. 2014237269, First Examination Report dated Dec. 11, 2017”, 6 pgs. |
| “Australian Application Serial No. 2014237679, First Examination Report dated Dec. 11, 2017”, 4 pgs. |
| “Australian Application Serial No. 2014238304, First Examination Report dated Jan. 29, 2018”, 4 pgs. |
| “Australian Application Serial No. 2014238363, First Examination Report dated Feb. 8, 2018”, 3 pgs. |
| “Australian Application Serial No. 2014238367, First Examination Report dated Feb. 16, 2018”, 3 pgs. |
| “Chinese Application Serial No. 201480027178.3, Office Action dated Oct. 10, 2017”, W/ English Translation, 14 pgs. |
| “Chinese Application Serial No. 201480027655.6, Response filed Oct. 9, 2017 to Office Action dated May 15, 2017”, W/ English Translation of Claims, 9 pgs. |
| “European Application Serial No. 10754613.7, Communication Pursuant to Article 94(3) EPC dated Nov. 28, 2017”, 3 pgs. |
| “European Application Serial No. 14707909.9, Summons to Attend Oral Proceedings dated Oct. 18, 2017”, 2 pgs. |
| “European Application Serial No. 14709014.6, Summons to Attend Oral Proceedings dated Oct. 18, 2017”, 2 pgs. |
| “European Application Serial No. 14714491.9, Communication Pursuant to Article 94(3) EPC dated Feb. 8, 2018”, 6 pgs. |
| “European Application Serial No. 14714491.9, Response filed Oct. 16, 2017 to Non Final Office Action dated Feb. 28, 2017”, 18 pgs. |
| “European Application Serial No. 14724817.3, Response filed Nov. 9, 2017 to Office Action dated Jun. 29, 2017”, 19 pgs. |
| “European Application Serial No. 14729994.5, Communication Pursuant to Article 94(3) EPC dated Oct. 10, 2017”, 8 pgs. |
| Bendinelli, Paola, et al., “Molecular Basis of Anti-Inflammatory Action of Platelet-Rich Plasma on Human Chondrocytes: Mechanisms of NF-kB Inhibition Via HGF”, Journal of Cellular Physiology 225, (2010), 757-766. |
| Le Meur, Yannick, et al., “Whole blood production of monocytic cytokines (IL-1β, IL-6, TNF-a, sIL-6R, IL-1Ra) in haemodialysed patients”, Nephrology Dialysis Transplantation; 14, (1999), pp. 2420-2426. |
| Ulich, Thomas R., et al., “Endotoxin-Induced Cytokine Gene Expression in Vivo: IV. Expression of Interleukin-1 a/ß and Interleukin-1 Receptor Antagonist mRNA During Endotoxemia and During Endotoxin-initiated Local Acute Inflammation”, American Journal of Pathology, vol. 141, No. 1, (Jul. 1992), pp. 61-68. |
| Woodell-May, J. et al. “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting” Scientific Foundation, Journal of Carniofacial Surgery, vol. 16, No. 5 (pp. 749-756) Sep. 2005. |
| Woodell-May, J. et al. Autologous protein solution inhibits MMP-13 production by IL-1beta and TNFalpha-stimulated human articular chondrocytes. J Orthop Res Sep. 15, 2011; 29:1320-6. |
| Wright-Carpenter, T. “Treatment of Muscle Injuries by Local Administration of Autologous Conditioned Serum: A Pilot Study on Sportsmen with Muscle Strains” Int J Sports Med, vol. 25 (pp. 588-593) Oct. 2004. |
| Yang, S. et al. “Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis” Gene Therapy, vol. 11 (pp. 483-491) 2004. |
| Yang, T. et al. “Recent Applications of Polyacrylamide as Biomaterials” Recent Patents on Materials Science, vol. 1 (pp. 29-40) 2008. |
| Yoshida S. et al. “Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma” Clinical and Experimental Immunology, Wiley-Blackwell Publishing Ltd. vol. 106, No. 1, Oct. 1996. |
| Zhang et al.“IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats” PAIN. vol. 135, No. 3, Mar. 5, 2008, pp. 232-239. |
| “Australian Application Serial No. 2014237269, Response filed Jul. 28, 2018 to Subsequent Examiners Report dated Jun. 29, 2018”, 15 pgs. |
| “Australian Application Serial No. 2014237269, Subsequent Examiners Report dated Jun. 29, 2018”, 10 pgs. |
| “Australian Application Serial No. 2014237679, Response filed Jul. 19, 2018 to Subsequent Examiners Report dated May 29, 2018”, 54 pgs. |
| “Australian Application Serial No. 2014238304, Subsequent Examiners Report dated Jun. 9, 2018”, 3 pgs. |
| “Chinese Application Serial No. 201480027178.3, Office Action dated Jun. 15, 2018”, w/ English translation, 9 pgs. |
| “European Application Serial No. 10754613.7, Communication Pursuant to Article 94(3) EPC dated Jun. 26, 2018”, 3 pgs. |
| “U.S. Appl. No. 12/394,723, Corrected Notice of Allowability dated Jul. 30, 2018”, 5 pgs. |
| “U.S. Appl. No. 12/394,723, Notice of Allowance dated Jul. 17, 2018”, 10 pgs. |
| “U.S. Appl. No. 13/837,480, Notice of Allowance dated Jun. 28, 2018”, 7 pgs. |
| “U.S. Appl. No. 14/973,913, Final Office Action dated Aug. 9, 2018”, 11 pgs. |
| “U.S. Appl. No. 15/836,249, Response filed Jul. 2, 2018 to Non Final Office Action dated Apr. 6, 2018”, 11 pgs. |
| U.S. Appl. No. 14/271,722, filed May 7, 2014, Higgins et al. |
| U.S. Appl. No. 13/840,562, filed Mar. 15, 2013, Binder et al. |
| U.S. Appl. No. 13/841,083, filed Mar. 15, 2013, Landrigan et al. |
| U.S. Appl. No. 13/837,005, filed Mar. 15, 2013, Woodell-May et al. |
| U.S. Appl. No. 13/837,480, filed Mar. 15, 2013, O'Shaughnessey et al. |
| U.S. Appl. No. 13/840,129, filed Mar. 15, 2013, Matuska et al. |
| U.S. Appl. No. 13/841,103, filed Mar. 15, 2013, Landrigan et al. |
| U.S. Appl. No. 15/836,249, filed Dec. 8, 2017, Treatment of Peripheral Vascular Disease Using Protein Solutions. |
| Number | Date | Country | |
|---|---|---|---|
| 20140274894 A1 | Sep 2014 | US |
